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2007 Rock Øyen Symposium
This issue of Immunohematology contains a 
series of papers that formed the basis of a seminar 
held at the New York Blood Center in November 
2007.  The seminar, titled “Understanding Molecular 
Analysis for Prediction of Blood Groups,” was the 
first annual meeting to honor the contributions of 
Ragnhild “Rock” Øyen and Carol Johnson to the field 
of immunohematology.  Rock and Carol had much in 
common: both were technologists, scientists, educa-
tors, and friends who worked together as colleagues 
at NYBC for more than 30 years and published 
numerous papers, reviews, and textbook chapters. 
They loved the work and the people, epitomized 
good customer service and relations, and were well 
respected.  Tragically, both died prematurely in 2007 
after courageously fighting cancer.  The seminar was 
sponsored by the Immunohematology Education 
Fund, whose purpose and mission is to encourage 
medical technologists to follow Rock and Carol’s role 
model and embrace a career in immunohematology. 
Although managed and administered by the New 
York Blood Center, this fund supports technologist 
and SBB education across the country.
The first paper, “From DNA to Blood Groups,” 
by Marion Reid, provides an overview of how blood 
groups are encoded by changes in DNA sequence. 
The second paper, “Principles of PCR-Based Assays,” 
describes techniques used in a molecular biology 
laboratory to predict blood group antigens, and is 
contributed by Kim Hue-Roye and Sunitha Vege. 
This paper is followed by a review of how the re-
sults of DNA testing can be applied to donors, by 
Donna Strauss and Marion Reid, entitled “Value of 
DNA Testing for Donor Screening and Regulatory 
Issues,” and a review by Christine Lomas-Francis 
and Helene DePalma entitled “DNA-Based Assays 
for Patient Testing: Their Application, Interpretation, 
and Correlation of Results.”  It is clear that DNA test-
ing is an invaluable adjunct to hemagglutination, and 
scenarios in which DNA testing can be used to over-
come long-standing limitations of hemagglutination 
are described.  The final paper in the series explains 
how more precise matching of donor RBC compo-
nents with patients may be possible and feasible at 
the DNA level, especially for certain patient popula-
tions, and is entitled “The Potential of Blood Group 
Genotyping for Transfusion Medicine Practice,” by 
Connie Westhoff.
We think Rock Øyen and Carol Johnson would 
have enjoyed the seminar and would have marveled 
at the potential for DNA testing to enhance the 
provision of antigen-negative RBC components and 
the selection of compatible blood for transfusion. 
Indeed, we hope you also enjoy this “molecular 
journey” highlighting, in our opinion, the most sig-
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From DNA to blood 
groups
m.e. reiD
A blood group antigen is a protein or carbohydrate on the 
outer surface of a RBC.  Portions of DNA are transcribed and 
translated into proteins.  A protein-based blood group antigen 
is the direct product of a gene whereas a carbohydrate-based 
blood group antigen is an indirect product of a gene; the gene 
product is a glycosyltransferase that transfers a carbohydrate 
moiety to a protein, or to another carbohydrate to form a chain 
of sugars.  This report gives a brief description of a gene, its 
processing from DNA through RNA to an amino acid sequence, 
and how changes in nucleotides give rise to blood group anti-
gens.  Immunohematology 2008;24:166–169.
Key Words: application of molecular testing for blood 
groups in transfusion medicine, blood group alleles, 
blood group antigens, DNA to protein, prediction of 
blood groups
A blood group antigen is a variant form of a protein 
or carbohydrate on the outer surface of a RBC that is 
identified when an immune response (alloantibody) 
is detected by hemagglutination in the serum of a 
transfused patient or pregnant woman.  The astound-
ing pace of growth in the field of molecular biology 
techniques and in the understanding of the molecular 
bases associated with most blood group antigens and 
phenotypes enables us to consider the prediction of 
blood group antigens using molecular approaches. 
Indeed, the knowledge is currently being applied to 
help resolve some long-standing clinical problems that 
cannot be resolved by classic hemagglutination.1  This 
report reviews the processing of DNA and molecular 
events that can lead to a blood group antigen.
Blood group antigens are inherited, polymor-
phic, structural characteristics located on proteins, 
glycoproteins, or glycolipids on the exofacial surface 
of the RBC membrane.  The classic method of testing 
for blood group antigens and antibodies is hemag-
glutination.  This method is simple and, when done 
correctly, has a specificity and sensitivity that is ap-
propriate for the clinical care of the vast majority of 
patients.  Indeed, direct and indirect hemagglutina-
tion tests have served the transfusion community 
well for, respectively, more than 100 and more than 
50 years.  However, in some aspects, hemagglutina-
tion has limitations.  For example, it gives only an 
indirect measure of the potential complications in an 
at-risk pregnancy, it cannot precisely indicate RHD 
zygosity in people with D+ RBCs, it cannot be relied 
on to type some recently transfused patients, and it 
requires the availability of specific reliable antisera. 
The characterization of genes and determination 
of the molecular bases of antigens and phenotypes 
has made it possible to use the PCR2,3 to amplify the 
precise areas of DNA of interest to detect alleles en-
coding blood groups and thereby predict the antigen 
type of a person.
From DNA to Blood Groups
The Language of Genes
DNA is a nucleic acid composed of nucleotide 
bases, a sugar (deoxyribose), and phosphate groups. 
The nucleotide bases are purines (adenine [A] and 
guanine [G]) and pyrimidine (thymine [T] and cyto-
sine [C]).  The language of genes is far simpler than 
the English language.  Compare four letters in DNA 
or RNA (C, G, A, and T [T in DNA is replaced by 
U in RNA]) with 26 letters of the English alphabet. 
These four letters (nucleotides) form “words” (called 
codons), each with three nucleotides in different 
combinations.  There are only 64 (4 × 4 × 4 = 64) pos-
sible codons, of which 61 encode the 20 amino acids 
and three are stop codons.  There are more codons 
(n = 61) than there are amino acids (n = 20) because 
some amino acids are encoded by more than one 
codon (e.g., UCU, UCC, UCA, UCG, AGU, and AGC 
all encode the amino acid serine).  This is known as 
redundancy in the genetic code.
Essentials of a Gene
Figure 1 shows the key elements of a gene. 
Exons are numbered from the left (5′, upstream) and 
are separated by introns.  Nucleotides (in groups of 
three) in exons encode amino acids or “stop,” whereas 
nucleotides in introns are not encoded.  Nucleotides 
in an exon are written in uppercase letters and those 
in introns and intervening sequences are written in 
lowercase letters.  At the junction of an exon to an 
intron there is an invariant sequence of four nucleo-
tides (AGgt) called the donor splice site, and at the 
junction of an intron to an exon is another invariant 
sequence of four nucleotides (agGT) called the accep-
tor splice site.  The splice sites interact to excise (or 
outsplice) the introns, thereby converting genomic 
DNA to mRNA.  A single strand of DNA (5′ to 3′) 
acts as a template and is duplicated exactly to form 
mRNA.  Nucleotide C invariably pairs with G, and A 
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silent (synonymous), missense (nonsynonymous), or 
nonsense single nucleotide change and examples 
involving blood group antigens are illustrated.
eFFeCt OF a single nuCleOtiDe Change On a BlOOD 
grOup
Owing to redundancy in the genetic code, a silent 
(synonymous) nucleotide change does not change 
which amino acid is encoded and, thus, does not af-
fect the antigen expression.  Nevertheless, because it 
is possible that such a change could alter a restriction 
enzyme recognition site or a primer binding site, it 
is important to be aware of silent nucleotide changes 
when designing a PCR-based assay.  In contrast, a 
missense (nonsynonymous) nucleotide change results 
in a different amino acid, and these alternative forms 
of the allele encode antithetical antigens.  Figure 2 
illustrates this for the situation in which G in a lysine 
codon (AAG) is replaced by C, which gives rise to the 
codon for asparagine (AAC).  The example of a mis-
sense nucleotide change shows that a C to T change 
is the only difference between k and K.  A nonsense 
nucleotide change results in a codon for an amino 
acid to become a stop codon.  Figure 2 and Table 2 
give examples relative to blood groups.
Rock Øyen: DNA to blood groups
with T.  Upstream from the first exon of a gene there 
are binding sites (promoter regions) for factors that 
are required for transcription (from DNA to mRNA) of 
the gene.  Transcription of DNA always begins at the 
ATG, or “start,” transcription codon.  The promoter 
region can be ubiquitous, tissue-specific, or switched 
on under certain circumstances.  At the 3′ end of 
a gene there is a “stop” transcription codon (TAA, 
TAG, or TGA), and beyond that there is often an 
untranslated region (UTR).  Between adjacent genes 
on a chromosome there is an “intervening” sequence 
of nucleotides, which is not transcribed.
After the introns are excised, the resultant mRNA 
contains nucleotides from the exons of the gene. 
Nucleotides in mRNA are translated (from mRNA 
to protein) in sets of three (a codon) to produce 
a sequence of amino acids, which form a protein. 
Translation of mRNA always begins at the AUG, or 
“start,” codon and terminates at a “stop” codon (UAA, 
UAG, or UGA).  The resultant protein consists of 
amino acids starting with methionine (whose codon 
is AUG) at the amino (NH2) terminus.  Methionine, 
or a “leader” sequence of amino acids, is sometimes 
cleaved from the functional protein, and thus a writ-
ten sequence of amino acids for a mature protein 
does not necessarily begin with methionine.
Molecular Bases of Blood Groups
Although many mechanisms give rise to a blood 
group antigen or phenotype (Table 1), the majority of 
blood group antigens are a consequence of a single 
nucleotide change.  The other mechanisms listed 
give rise to a small number of antigens and various 
phenotypes.  Figure 2 shows a short hypothetical se-
quence of DNA together with transcription (mRNA) 
and translation (protein) products.  The effect of a 
Table 1. Molecular events that give rise to blood group antigens and 
phenotypes
Molecular Mechanism Example for Blood Group
Single nucleotide changes in mRNA  See Figure 2 and Table 2
Single nucleotide change in a T>C in GATA of FY 
transcription site
Single nucleotide change in a  ag>aa in Jk(a–b–) 
splice site
Deletion of a nucleotide(s) See Figure 2 and Table 2
Deletion of an exon(s)  Exon 2 of GYPC in Yus 
phenotype
Deletion of a gene(s) RHD in some D– people
Insertion of a nucleotide(s) See Figure 2 and Table 2
  37-bp insert in RHD (RHDψ) in 
some D– people
Insertion (duplication) of an exon(s) Exon 3 of GYPC in Ls(a+)
Alternative exon Exon 1 in I– people
Gene crossover, conversion, other  Many hybrid genes in MNS 
recombination events and Rh systems
Alternative initiation (leaky GPD 
translation)
Absence/alteration of a required  RhAG in regulator Rhnull, and 
interacting protein Rhmod
Presence of a modifying gene  In(Lu) in dominant Lu(a–b–)
Unknown Knull, Gy(a–)
GPD = Glycophorin D, RhAG = Rh associated glycoprotein, which is required for 
expression of Rh antigens
Fig. 1. Anatomy of a gene.
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eFFeCt OF DeletiOn Or insertiOn OF nuCleOtiDe(s)
A deletion of one nucleotide results in a –1 frame-
shift and an eventual stop codon (Fig. 2 and Table 2). 
Typically, this leads to the encoding of a truncated 
protein, but it can cause elongation.  For example, 
a deletion of C close to the stop codon in the A2 
m.e. reiD
allele results in a transferase with 21 amino acids 
more than in the A1 transferase.4  Deletion of one 
nucleotide results in a –1 frameshift and a premature 
stop codon.  Similarly, deletion of two nucleotides re-
sults in a –2 frameshift and a premature stop codon. 
Deletion of a nucleotide can cause a stop codon, but 
there is no known example for a blood group.
An insertion of one nucleotide results in a +1 
frameshift and a premature stop codon (Fig. 2 and 
Table 2).  Insertion of two nucleotides results in a +2 
frameshift and a premature stop codon.  Insertion of 
a nucleotide can cause a stop codon, but there is no 
known example for a blood group.
Molecular Bases of Blood Group Antigens
The genes encoding 28 of the 29 blood group 
systems (only P1 remains to be resolved) have been 
cloned and sequenced.5  Focused sequencing of DNA 
isolated from blood obtained from patients or donors 
with serologically defined antigen profiles has been 
used to determine the molecular bases of variant 
forms of the gene.  This approach has been extremely 
powerful because antibody-based definitions of 
blood groups readily distinguish variants within each 
blood group system.  Details of these analyses are 
beyond the scope of this paper, but up-to-date details 
about alleles encoding blood groups can be found 
on the blood group antigen gene mutation database 
at: http://www.ncbi.nlm.nih.gov/projects/mhc/xslcgi.
fcgi?cmd=bgmut/systems, or by entering “dbRBC” in 
a search engine.  Suffice it to say that there are 29 
blood group systems, 34 gene loci, more than 250 
antigens, and close to 1,000 alleles that encode the 
blood group antigens and phenotypes.
Once the molecular basis of a blood group an-
tigen has been determined, the appropriate part of 
the DNA can be analyzed to predict the presence or 
absence of a blood group antigen on the surface of 
an RBC.  Fortunately, as the majority of genetically 
defined blood group antigens are the consequence of 
a single nucleotide change, simple PCR-based assays 
can be used to detect a change in a gene encod-
ing a blood group.  Figure 3 illustrates examples 
of read-outs for commonly used assays.  Numerous 
DNA-based assays have been described for this pur-
pose and will be described in a subsequent paper.
Summary
Numerous studies have analyzed blood samples 
from people with known antigen profiles and 
Fig. 2. A hypothetical sequence of DNA and the effect of a single 
nucleotide change.
Table 2. Molecular bases associated with a few blood group antigens
Antigen/  Nucleotide 
Phenotype Gene Change Amino Acid
Missense nucleotide change
S/s GYPB 143T>C Met29Thr
E/e RHCE 676C>G Pro226Ala
K/k KEL 698T>C Met193Thr
Fya/Fyb FY 125G>A Gly42Asp
Jka/Jkb JK 838G>A Asp280Asn
Doa/Dob DO 793A>G Asn265Asp
Nonsense nucleotide change
Fy(a–b–) FY 407G>A Try136Stop
D– RHD 48G>A Trp16Stop
Gy(a–) DO 442C>T Gln148Stop
Nucleotide deletion
D– RHD 711Cdel Frameshift→245Stop
D– RHD AGAG Frameshift→167Stop
Nucleotide insertion
Ael ABO 798-804Gins Frameshift→Stop
D– RHD 906GGCTins Frameshift→donor 
   splice site change 
   (I6+2t>a)
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identified the molecular bases associated with many 
antigens.4,6  The available wealth of serologically de-
fined variants has contributed to the rapid rate with 
which the genetic diversity of blood group genes 
has been revealed.  Although PCR-based assays have 
limitations, they nevertheless have several clinical 
applications, which are described in subsequent 
papers in this issue of Immunohematology.
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Fig. 3. From cell nucleus to DNA to assays used to predict a blood type.
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Principles of PCR-based 
assays
K. hue-rOye anD s. vege
DNA-based assays are powerful tools to predict the blood group 
of an individual and are rapidly gaining in popularity.  DNA, 
which can be extracted from various sources using commercial 
kits, is amplified by PCR to obtain a sufficient amount of the 
target of interest for analysis.  There are different types of PCR 
assays: standard single PCR (followed by RFLP or sequenc-
ing), allele-specific PCR, multiplex PCR, and real-time PCR. 
Microarray platforms are a newer application of molecular 
testing, popular because they analyze multiple nucleotides in a 
single assay and have a high-throughput potential.  This review 
briefly describes the principles of PCR-based assays that are 
commonly used in transfusion medicine. Immunohematology 
2008;24:170–175.
Key Words: DNA, PCR, BeadChip, RFLP, blood group 
sequencing, molecular analysis
The molecular genetics world was revolutionized 
in 1983 with the advent of PCR,1 which allows the 
amplification of DNA and analysis of genes.  Since 
the development of this tool, the molecular genetics 
field has greatly expanded, and the method has been 
used to answer a variety of questions in numerous 
areas, including forensics, evolution, archeology, and, 
in recent years, transfusion medicine.
RBC agglutination is still the conventional test 
method for detecting blood group antigens and 
antibodies as it is relatively inexpensive and quick 
and requires minimal equipment.  However, it is not 
without its limitations.  Typing multiply transfused 
patients, a lack of rare or reliable potent antisera, and 
encountering reagent discrepancies are just some 
situations in which serology is not straightforward. 
Molecular testing is useful in these instances, and it 
can be applied now that the genes encoding many 
of the blood group antigens have been cloned and 
sequenced.  Also, most blood group antigens are 
differentiated by single-nucleotide polymorphisms 
(SNPs) at the DNA level that change the amino acid 
at the protein level, and these polymorphisms can 
be targeted using PCR assays.  The applications are 
further described in other papers in this series.2–4
Test Environment and Equipment
Unlike traditional blood bank laboratories where 
most work can be done at a single workstation, 
molecular laboratories must separate “clean” and 
“dirty” processes, and, ideally, locate each in a sepa-
rate room.  “Clean,” or pre-PCR, processes include 
DNA extraction and PCR setup.  “Dirty,” or post-PCR, 
processes include analysis or any testing done on 
the PCR-amplified products.  Separation is necessary 
to prevent contamination among samples and, most 
importantly, to prevent PCR-amplified products from 
contaminating patient and donor DNA samples.  The 
different processes must have separate equipment 
and supplies to further minimize contamination. 
Laboratories use micropipette filter tips to minimize 
aerosols and decontaminate surfaces and equipment 
with dilute bleach or a DNA removal agent.  UV light 
exposure can also be used on surfaces and equip-
ment to degrade any potential contaminating DNA.
Extraction of DNA
Genomic DNA can be extracted from various 
sample sources such as peripheral whole blood, 
urine, amniotic fluid, buccal swabs, and dried blood 
spots on filter paper (QIAamp DNA Blood Mini Kit, 
QIAGEN, Valencia, CA).  For blood samples, EDTA 
is the preferred coagulant, but other coagulants, 
such as citrate, are acceptable.  Lithium heparin is 
discouraged because heparin can interfere with the 
PCR reaction.  DNA is very stable, and samples sent 
for molecular testing can be weeks or months old, 
but optimal samples are less than 3 days old, stored 
at refrigerator temperatures.
There are many commercial kits available that 
make the process of extracting genomic DNA rela-
tively easy.  Compared with early methods that used 
desalting and phenol/chloroform, the extraction 
process is now fast, reliable, and nontoxic.  DNA 
extraction using commercial kits removes proteins 
and other contaminants, which may inhibit PCR, and 
yields DNA of high quality in less than 1 hour.
Polymerase Chain Reaction (PCR)
PCR is used to amplify a specific region of DNA 
that harbors the nucleotide(s) of interest, i.e., for a 
blood bank, this is the region that encodes the blood 
group antigen.  The PCR reaction mixture consists of 
a reaction buffer, magnesium chloride, deoxynucleo-
tide-triphosphates (dNTPs) (G, A, T, C), oligonucleotide 
primers complementary to the gene of interest, heat-
stable enzyme Taq polymerase (which is isolated from 
the bacterium Thermus aquaticus), and the DNA of 
interest.  Primers typically range from 18 to 36 base 
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Manual PCR Assays
Various PCR assays commonly used include 
allele-specific (AS)-PCR, PCR-restriction fragment 
length polymorphism (RFLP), and multiplex PCR. 
AS-PCR requires two reactions to be set up for each 
DNA sample.  In this type of PCR assay, each reaction 
tube has one primer that is gene-specific (i.e., com-
mon to both alleles), and one primer that is specific 
for one of the two possible alleles present.  After 
PCR amplification, no additional manipulation of the 
PCR products is required, and they are visualized by 
agarose gel electrophoresis (Fig. 2).  Because the lack 
of a PCR product indicates an allele is not present, 
a positive internal control consisting of primers that 
will amplify a product in all samples is needed as a 
control for the PCR reaction.
In PCR-RFLP methods, one PCR reaction is per-
formed and the two primers are gene-specific.  The 
alleles are differentiated after PCR by digestion of the 
products with a restriction enzyme.  Restriction en-
zymes, which are commercially available, are highly 
specific and cleave a unique 4- or 6-bp sequence of 
nucleotides (Fig. 3A).  Alleles are discriminated by 
the fragment pattern visualized by gel electrophoresis 
after digestion.  The fragment pattern is compared 
with those of known controls tested in parallel.  The 
controls used are generally a homozygous allele A, 
a homozygous allele B, and a heterozygote A/B (Fig. 
3B).
Typically, AS-PCR and PCR-RFLP target a single 
allele.  Multiplex PCR enables simultaneous ampli-
fication of many target alleles or regions of DNA in 
one reaction by using multiple primer pairs.  This al-
lows for a reduction in the number of different assays 
performed and saves time and reagents.  However, 
multiplexing has limitations in the number of primer 
pairs that can be combined in one reaction, and the 
initial optimization of multiplex assays can be tech-
nically challenging and difficult.  Primer annealing 
temperatures need to be similar, and all the reaction 
components must be carefully optimized to avoid 
false-priming of primers and amplified products. 
After multiplex PCR, products are visualized on aga-
rose gels and discriminated by fragment sizes.
Sequencing
Another often-used PCR analysis involves puri-
fication followed by direct gene sequencing of the 
PCR product.  Sequencing is an automated proce-
dure, typically performed by a sequencing facility.  It 
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pairs (bp) and are designed to amplify relatively short 
DNA segments, usually 200 to 800 bp in length.  The 
tube with the PCR reactants is placed in a thermal 
cycler programmed for a series of cycles that consist 
of heating at 95°C to denature the DNA, followed 
by cooling at 55° to 65°C to anneal the primers to 
the DNA template, and heating again to 72°C for the 
heat-stable Taq polymerase to synthesize the DNA 
between the primers.  Figure 1 outlines the principles 
of PCR amplification.  In step 1, the denaturation step, 
the double-stranded DNA is made single-stranded 
by the high temperature of 95°C.  In step 2, the an-
nealing step, the oligonucleotide primers, which are 
complementary to the gene target of interest, bind to 
the single-stranded DNA.  The annealing temperature 
used is dependent on the length, nucleotide sequence, 
and particularly the G/C content, of the primers and 
typically ranges from 55°C to 65°C.  In step 3, the exten-
sion step, the Taq polymerase adds dNTPs to the end 
of the primer complementary to the DNA template to 
which it annealed, thereby creating an exact copy and 
double-stranded DNA.  These steps are repeated 25 to 
35 times, which results in an exponential increase in 
the number of copies of the specific area of interest 
(PCR amplicon).  The PCR products are subjected to 
analysis by any number of different methods, which 
can include electrophoresis to separate the fragments 
through an agarose gel, based on size, with the frag-
ment bands visualized by ethidium bromide staining 
and UV light.  Alternatively, the products may be 
digested with enzymes, sequenced directly, or read 
by automated readout systems (discussed in a later 
section).
Fig. 1. Principle of PCR amplification.  (1) Denaturation step at 95°C 
to separate double-stranded DNA.  (2) Annealing step typically 
at 55° to 65°C for binding of primer to single-stranded DNA. 
(3) Extension step at 72°C for the creation of an exact double-
stranded DNA copy.
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involves an additional PCR performed on the initial 
PCR products using dideoxynucleotides (ddNTPs) 
that are fluorochrome-labeled bases.  Each base (A, 
C, T, and G) is represented by a color peak on a 
scan, which is known as an electropherogram scan 
(Fig. 4).  In this method, the nucleotide sequence 
of the PCR product is interpreted by comparison to 
the known sequence.  It is optimal for investigating 
multiple changes in a specific region of DNA and 
identifying previously unknown nucleotide changes 
in the gene sequence.
Real-Time PCR
In real-time PCR, the amplified products are 
monitored in real time by measuring the fluorescence 
emitted by a reporter molecule after each cycle of 
amplification.  There are different types of fluores-
cent reporter molecules, including those that bind to 
double-stranded DNA molecules (i.e., SYBR Green) 
and those that bind to specific DNA sequences (i.e., 
Molecular Beacons or TaqMan Probes), which can 
be purchased from various commercial vendors. 
Unlike PCR assays already described, real-time PCR 
is a semiautomated method that does not require an 
additional gel electrophoresis step; rather, the fluo-
rescence intensities are monitored and interpreted by 
computer.
SYBR Green
Real-time PCR reactions contain reagents similar 
to those in the PCR assays described earlier but with 
the addition of a fluorescent dye.  SYBR Green has 
little fluorescence, but when the dye is bound to 
double-stranded DNA, fluorescence is emitted.  After 
Fig. 2. Allele-specific PCR assay.  A. Two reactions are set for each sample.  Each reaction has a gene-specific primer common to both reactions 
and an allele-specific primer for the allele of interest.  B. AS-PCR reactions run on a 1% agarose gel.  (Lane 1) DNA ladder; (lanes 2–7) PCR 
products from six samples using a GYP*BS allele-specific primer; (lane 8) negative control containing no DNA; (lanes 9–14) PCR products 
from same six samples using GYP*Bs allele-specific primer; and negative control containing no DNA.  An additional pair of primers is used 
as an internal control for PCR amplification and the product is not related to the gene of interest.
Fig. 3. PCR-RFLP.  A. Recognition sites for allele JK*A and allele JK*B 
are shown.  Digestion with the restriction enzyme, MnlI, will 
discriminate between the two alleles.  JK*A will be cleaved in 
three positions, resulting in four fragments, whereas JK*B will 
be cleaved in two positions, resulting in three fragments.  B. 
Reactions run on a 2% agarose gel.  The ability to visualize 
the 22-bp fragment depends on the type and concentration 
of the gel.  (Lane 6) DNA ladder; (lane 5) DNA amplicon not 
digested with the restriction enzyme; lane 4) no DNA control; 
(lanes 1–4) PCR products digested with the restriction enzyme, 
MnlI.  
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each PCR cycle, the fluorescence emitted is propor-
tional to the PCR product amount.  SYBR Green is 
inexpensive and binds to all double-stranded DNA. 
Nonspecific PCR products can be differentiated from 
PCR products by melting-curve analysis.  Multiplexing 
is not possible.
TaqMan Probes
Real-time PCR reactions involve using DNA-spe-
cific probes that can be labeled with different color 
dyes (TAM, TET, JOE, VIC, SYBR Green), which allows 
for multiplexing.  Sequence-specific probes, such as 
TaqMan probes, are labeled with a reporter fluores-
cent dye and a quencher dye.  When the two dyes are 
in close proximity, there is little fluorescence.  If an 
allele is present and the probe binds during the PCR 
reaction, the Taq polymerase cleaves the reporter dye, 
separating it from the quencher and emitting fluores-
cence (Fig. 5).  Although TaqMan probes allow for 
multiplexing, the number of targets is limited by the 
number of fluorescent dyes commercially available 
(typically two to four) and by the number of colors 
recognized by the instrument.  Characteristics of the 
different PCR assays are summarized in Table 1.
Automation
Manual PCR methods, such as AS-PCR and 
PCR-RFLP, are labor- and time-intensive, and PCR se-
quencing and real-time PCR are costly.  Determination 
of numerous polymorphisms covering multiple 
systems with these assays would take days, making 
the possibility of mass donor screening impossible. 
Therefore, automation of the process is needed for 
rapid, cost-effective typing.
DNA extraction is also a labor- and time-inten-
sive process.  Several commercial companies have 
automated robotic instruments for extraction of 96 
samples in as little as 2 hours.  These instruments 
have similar chemistries to those of the manual ex-
traction kits.
Microarray and BeadChip platforms have recently 
been introduced for the automation of prediction of 
Table 1. Characteristics of various PCR assays
Characteristic AS-PCR PCR-RFLP Multiplex Sequencing Real-Time PCR Array Platforms
Manual process √ √ √
Labor- and time-intensive √ √ √ √
Extensive optimization √  √  √
Quantification     √
Single SNP √ √ √
Multiple SNPs   √ √ √
High throughput      √
Requires additional equipment    √  √
Donor screening      √
AS-PCR = allele-specific polymerase chain reaction; PCR-RFLP = polymerase chain reaction–restriction fragment length polymorphism; SNP = single-nucleotide 
polymorphism.
Fig. 4. Electropherogram of a sequence of DNA.  Each base (A, C, 
T, and G) is represented by a color peak on a scan, and the 
nucleotide sequence is displayed.  In a single position with 
two peaks, an “N” (indicated by arrow) shows that the sample 
is heterozygous for nucleotides A and G at that position.
Fig. 5. Real-time PCR with sequence-specific probes.  A. Sequence-
specific probe with reporter (R) and quencher (Q) dye bound 
to the DNA strand.  Little fluorescence is emitted.  B and C. PCR 
product extends and the Taq polymerase cleaves the reporter 
dye and separates it from the quencher dye.  Fluorescence is 
emitted.
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blood group antigens.  The steps in testing include an 
initial multiplex PCR reaction, followed by hybridiza-
tion to oligonucleotide probes either bound to glass 
slides or bound to beads, with fluorescence signals 
indicating the presence or absence of an allele.
The platform from Progenika (BloodGen Project; 
Cambridge, MA) includes allele-specific oligonucle-
otide probes bound to a modified glass slide.  The 
PCR involves several separate multiplex reactions 
that simultaneously amplify numerous targets for 
nine blood group systems.  The blood group–specific 
primers are labeled at the 5′ region with a universal 
tag that allows for increased specificity and more 
consistent yield of all PCR products.  After amplifica-
tion, the PCR products are labeled with Cy fluorescent 
dyes, fragmented with DNAse I, hybridized to the 
glass slides, and washed.  An array scanner scans 
the slides, and the software reads the fluorescent 
intensity to identify alleles and determine genotypes 
and predicted phenotypes.  Currently, the Progenika 
BLOODchip targets 116 SNPs for ABO, RHD (com-
mon weak D, partial D, Del, and D negative), RHCE 
(C/c, E/e, VS, V, CX, CW), Kell (K/k, Jsa/b, Kpa/b/c, 
Kmod-1), Kidd, Duffy (Fya/b/x, Fy null), MNS (M/N, 
S/s, U, Gp.Mur), Dombrock (Doa/b), Colton (Coa/b), 
and Diego (Dia/b).5
BioArray Solutions Ltd. (Warren, NJ), now part 
of Immucor, developed a BeadChip platform that 
uses color-coded beads coated with allele-specific 
oligonucleotides.  These beads are randomly im-
mobilized onto a silicone wafer chip (BeadChip). 
One multiplex PCR reaction is used to amplify the 
blood group targets.  After the PCR, the products 
are made single-stranded and hybridized to the 
BeadChip.  If the PCR products are complementary 
to the oligonucleotide, indicating the allele is pres-
ent, a DNA polymerase will extend the strand and 
incorporate fluorescently labeled dNTP.  A snapshot 
of fluorescent intensities is taken and decoded using 
the software that determines the intensity ratio for 
paired probes, interprets the data, and interprets the 
results as both a genotype and predicted phenotype. 
The process from start to finish is approximately 
5 hours.6  Both automated platforms are substan-
tially faster than manual PCR assays and allow for 
high-throughput testing.  The Human Erythrocyte 
Antigen (HEA) BeadChip includes probes that detect 
the polymorphisms for K/k, Kpa/b, Jsa/b, Jka/b, Fya/Fyb/
weakened Fyb/Fy GATA, M/N, S/s/UVAR, Rh C/c and 
E/e, VS and V.  These platforms cannot detect rare 
alleles or silenced alleles unless the polymorphisms 
responsible are specifically targeted.  For example, 
the current HEA BeadChip targets only common 
silencing alleles in FY*B (GATA –33 t>c) and GYP*B 
(S–s–UVAR intron 5 +5g>t and 230C>T).
Conclusion
Agglutination will not become obsolete in blood 
banking as molecular testing is a prediction of the 
RBC phenotype and cannot replace antibody iden-
tification and screening.  Molecular analysis is a 
valuable adjunct to hemagglutination for the predic-
tion of antigen status or resolution of a discrepancy,7 
and it is an important tool for resolving complex 
serology cases, typing multiply transfused patients, 
and performing large-scale donor screening.
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Value of DNA-based  
assays for donor 
screening and  
regulatory issues
D. strauss anD m.e. reiD
Hemagglutination, the gold standard method to detect the pres-
ence or absence of blood group antigens on RBCs, has served 
the transfusion community well for decades.  It is simple, and, 
when done correctly, it has a specificity and sensitivity that is 
appropriate for most testing in the vast majority of patients 
requiring blood transfusion.  The limitations of hemagglutina-
tion for screening donor blood include that both testing and 
data entry are labor-intensive, that the required antibody is not 
always commercially available, and that it may be limited in 
volume, weakly reactive, or costly.  These scenarios can make it 
difficult to screen for large numbers of antigen-negative blood 
donors.  The knowledge of the molecular bases of blood group 
antigens makes it possible to screen donors to predict their 
antigen status.  High-throughput platforms provide a means 
to test relatively large numbers of donors, thereby opening the 
door to change the way antigen-negative blood is provided to 
patients.  This review discusses testing for blood group anti-
gens by hemagglutination and bead chip technology.  It also 
reviews regulatory issues, including validation and training, 
and suggests an algorithm for screening and confirming blood 
types of donors.  Immunohematology 2008;24:175–179.
Key words: DNA testing, donor testing, blood group 
antigens, hemagglutination
Typing for Blood Group Antigens in Donors
Testing for the presence or absence of a blood 
group antigen has traditionally been done by pheno-
typing using serologic methods.  However, it is now 
possible to predict the presence or absence of a blood 
group by assaying DNA.  There are two basic types of 
PCR-based assays: laboratory-developed tests (LDTs), 
which were previously known as “homebrew” assays, 
and DNA arrays.
The decision as whether to use hemagglutina-
tion or DNA methodologies is dependent on various 
things, such as availability of reagents and the 
complexity of the molecular basis of an antigen’s 
phenotype.  For example, because of the complexity 
of genes encoding antigens and phenotypes in ABO 
and Rh blood group systems, DNA analysis is not the 
method of choice for routine ABO and D determina-
tion.  However, screening for donors by analyses of 
DNA is valuable for typing of the so-called minor 
blood group antigens and Rh variants, and for resolv-
ing apparent discrepancies.
Use of DNA-Based Assays to Predict the 
Antigen Type in Donors
DNA-based assays, with their high-throughput 
capability, can be used to mass screen donors, and 
they provide a tool to enable us not only to increase 
the antigen-negative inventory of combinations of 
the minor antigens but also to find donors whose 
RBCs lack a high-prevalence antigen, namely, U, UVar, 
Fy3, Lub, Dib, Hy, Joa, Sc1, LWa, or Cob.  This can lead 
to improved patient care by having the appropriate 
antigen-negative blood available.1  By using these 
high-throughput DNA-based methods as a screening 
tool, precious antisera can be conserved to be used 
to serologically confirm the results predicted by DNA 
typing.
DNA-based assays also can be useful to detect 
genes that are predicted to encode weakly expressed 
antigens and thereby prevent immunization or pos-
sible transfusion reactions.  As we now have options 
for how to test for antigen-negative donors, it is 
necessary to determine which method to use under 
which circumstances.  Table 1 lists suggestions for 
when to use hemagglutination and when to use mo-
lecular methods.
Testing for minor antigens
When the molecular basis of a blood group an-
tigen has been determined to be caused by a single 
nucleotide change or small deletion or insertion of 
nucleotides, simple PCR-based assays can be used to 
predict their presence or absence on RBCs.  There 
are numerous examples of this, e.g., K/k, Fya/Fyb, 
Jka/Jkb, S/s, Doa/Dob, and Yta/Ytb.2  PCR-based assays 
are particularly valuable to predict antigens when 
the available antibody is weak or the antibody is not 
readily available, e.g., anti-Doa, -Dob, -Jsa, -Jsb; -CW, -V, 
and -VS.  These assays are particularly valuable in the 
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Dombrock blood group system; typing for Doa, Dob, 
Hy, and Joa by hemagglutination is notoriously diffi-
cult because the corresponding antibodies, although 
clinically significant, are often weakly reactive, avail-
able only in small volume, and in sera containing 
other alloantibodies.  Testing for Do antigens by 
DNA analyses is accomplished without the need for 
special reagents (antibodies) and is the first example 
of where PCR-based assays surpass hemagglutination 
for antigen typing.3
To meet the antigen-negative RBC component 
needs of chronically transfused, immunized African 
American patients, it has been the practice to use RBC 
components from donors of the same ethnic origin. 
For such patients, a commonly needed phenotype is 
C–, E–, S–, K–, Fy(a–), and Jk(b–), which is most likely 
to be found in people of African origin.  However, 
these donors have immunogenic antigens on their 
RBCs that are of low prevalence in the random 
population but present in up to 20 percent in African 
Americans.2  Thus, we find that many of these patients 
now have made anti-Jsa, -V/VS, -Goa, and -DAK, and 
thus require RBC components lacking these antigens. 
Providing the RBC components lacking these antigens 
is difficult for several reasons: (1) patients make anti-
bodies to these antigens in addition to several others, 
e.g., anti-C, -K, -Fya, and -Jkb; (2) the antigens are not 
on antibody screening RBCs; and (3) the crossmatch 
is not always reliable in their detection.  Thus, al-
though African American donors are the best place 
to look for certain combinations of antigen negativity 
for transfusion to African Americans, their RBCs are 
likely to express these low-prevalence antigens.
Some of the numerous variants in the Rh blood 
group system are clinically relevant but difficult to 
distinguish by hemagglutination.  Of particular note 
are hrS and hrB, the absence of which are known 
to be encoded by several distinct alleles.4  Although 
several assays are required, DNA-based assays can 
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be used to differentiate these alleles.  This has the 
potential to be able to provide donor blood that is 
precisely matched to that of a patient.
Resolution of ABO and Rh discrepancies
DNA-based assays can be used to detect alleles 
that encode a blood type that is detected by some 
antibody reagents but not others.  Resolution of 
these apparent discrepancies is helpful to reveal that 
the different results obtained by hemagglutination 
are caused by a genetic variant (not reportable to the 
Food and Drug Administration [FDA]) and not by a 
reagent failure or technologist error (reportable to 
the FDA).  This is particularly pertinent to A, B, D, 
C, and e.
DNA Array Platforms
DNA arrays make it possible for multiple assays 
to be performed on one sample simultaneously so 
a large number of samples can be tested for a large 
number of nucleotide changes.  There is a low incre-
mental cost for each assay that is added to a DNA 
array.  Another advantage of this technology is that 
results can be analyzed and interpreted by computer, 
and there is the potential to directly download inter-
pretations to a donor database.
In 2007, 2355 donors of known genotypes cover-
ing 24 RBC antigens in 10 blood group systems were 
tested using a DNA array (HEA BeadChip, BioArray 
Solutions, Warren, NJ).5  There was concordance of 
4510 of 4534 antigen typings (99.5%).  The discor-
dances were attributable mostly to clerical errors 
found on the original reports, and for Ss as a result 
of silencing mutations, which is included in the HEA 
1.1 BeadChip.  This was a joint venture with the New 
York Blood Center (NYBC) and BioArray Solutions.
Validation of BioArray Solutions HEA 1.1 BeadChip 
at NYBC
The HEA 1.1 BeadChip was initially validated by 
NYBC, extracting DNA from 396 donor samples, with 
BioArray Solutions performing the assay.  Validation 
results are shown in Table 2.  Of the 8578 successful 
tests, 62 percent were predicted to be antigen-positive 
and 38 percent were predicted to be antigen-negative. 
Sixty-seven percent of the negative results were new 
results (no previous serology testing).  Of particular 
note, the testing revealed six new Sc1– donors, as 
well as three e– and many c–, and s– donors that 
have been confirmed by serology.
Table 1. Antigen typing by hemagglutination or molecular assays
Hemagglutination Molecular assays
Readily available antisera,  Antisera not readily available, e.g., 
e.g., Anti-k, -Kpb, -Jsb, and -Fy3  anti-Lub, -Dib, -Doa, -Dob, -Hy, -Joa, 
-Coa, -Sc1, -Yta ,Cw ,V, and VS
Molecular basis unknown,  Need high throughput, e.g., for any 
e.g., Vel–, Lan–, At(a–), or Jr(a–)  blood group where the molecular 
basis is relatively simple
Molecular bases known but  
multiple backgrounds,  
e.g., null phenotypes such  
as Rhnull, K0, Gy(a–), or McLeod
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A second validation of the HEA 1.1 BeadChip 
was subsequently performed with NYBC personnel. 
The operational qualification (OQ) consisted of 68 
samples with known RBC phenotypes, which con-
sisted of C/c, E/e, M/N, S/s, K/k, Fya/Fyb, and Jka/Jkb. 
Included in the OQ were six known samples (cell 
line) and controls tested in replicate.  The cell lines 
were provided by BioArray Solutions.  For the run to 
be considered valid, all cell line sample results were 
required to match the panel key and the negative 
control was required to be negative.  Sixty-seven of 
the 68 samples were found to be concordant with the 
historic records.  One sample did not correlate with 
the HEA 1.1 BeadChip test result.  Historically the 
sample tested c–, E– using serologic test-
ing.  The molecular test predicted that the 
sample would possess c and E antigens. 
Repeat hemagglutination and DNA testing 
by LDT confirmed both results.  This sam-
ple is being investigated further, but the 
lack of correlation is likely attributable to a 
silenced RHCE*cE allele.  For performance 
qualification, NYBC tested 960 specimens 
with unknown phenotypes.  Once tested, 
the results were confirmed with serology. 
There were no discordant results.
Regulatory Issues
The regulatory items that must be 
considered include state or city department 
of health regulations, as well as the FDA 
Code of Federal Regulations (CFR).  The 
new technology enables the user to obtain 
many more results than previously possible, 
therefore requiring decisions to be made 
regarding how to use the test results.  An 
example would be when a Do(a–) or Do(b–) 
donor is identified using the BioArray 
technology.  A decision needs to be made 
regarding the use of the component, the 
donor’s subsequent donations, and how to 
manage the unlicensed results in the com-
puter system.  Suggestions regarding these 
decisions are discussed below.
New York State Department of Health 
(NYS-DOH)
The submission to NYS-DOH for test 
approval consists of providing documen-
tation regarding methods used (standard 
operating procedures, equipment, re-
agents, assay limitations), sample requisition forms, 
result reports with disclaimer statements, references, 
validation protocol, results, and quality assurance 
measures.  Depending on the state regulations, it may 
also require the applicant to specify whether the test-
ing will be performed on patient or donor samples. 
Unless the testing is being used to determine disease 
status, the analyte applied for under the laboratory 
license is immunohematology, not molecular testing. 
This approval allows NYBC to use the tests for clini-
cal purposes.  No separate consent is required from 
the donor.  This applies to New York State; local laws 
may differ.
Table 2. NYBC validation results for HEA 1.1 BeadChip
    New 
Test name Successful Positive Negative negative 
 tests results results results Agreement Conflicts*
Antigen test C 104 104 0 0 0 0
Antigen test c 369 266 103 30 73 1
Antigen test Coa 377 377 0 0 0 0
Antigen test Cob 377 16 361 359 2 0
Antigen test Dia 358 10 348 348 0 0
Antigen test Dib 358 350 8 8 0 0
Antigen test Doa 373 189 184 183 1 0
Antigen test Dob 373 189 184 184 0 1
Antigen test E 355 54 301 73 228 1
Antigen test e 355 343 12 3 9 0
Antigen test Fya 371 169 202 48 154 1
Antigen test Fyb 370 193 177 50 127 1
Antigen test Hy 373 373 0 0 0 0
Antigen test Jka 375 298 77 31 46 1
Antigen test Jkb 373 229 144 46 98 0
Antigen test Joa 373 373 0 0 0 0
Antigen test K 379 15 364 96 268 0
Antigen test k 379 378 1 0 1 0
Antigen test Lua 299 10 289 289 0 0
Antigen test Lub 301 301 0 0 0 0
Antigen test LWa 365 365 0 0 0 0
Antigen test LWb 363 0 363 363 0 0
Antigen test M 366 265 101 94 7 0
Antigen test N 373 241 132 132 0 0
Antigen test S 371 133 238 66 172 2
Antigen test s 371 340 31 19 12 0
Antigen test Sc1 377 371 6 6 0 0
Totals 9578 5952 3626 2428 1198 8
*Conflicts were not resolved since HEA BeadChip 1.2 became available.
Note: Agreement column indicates the number of samples that had serologic results performed 
and were concordant with molecular results. 
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Blood group typing: FDA compliance
The FDA classifies test procedures into three 
categories that define when a test may be used 
for clinical use.  These are summarized in Table 3. 
Hemagglutination is listed in each category because it 
depends on the source of the reagent.  FDA-approved 
reagents are in the first column and do not need to 
be confirmed by another method, those prepared in-
house (as used in most reference laboratory testing) 
are in the second column, and those that have not 
been characterized and validated belong in the third 
column.  Tests performed using investigation use only 
(IUO) or research use only (RUO) reagents should be 
confirmed with a licensed reagent if available.  If 
such a reagent is not available, the crossmatch will 
suffice.
Testing algorithm used at NYBC
The algorithm below is an approach used at 
the NYBC that allows efficient and effective use of 
reagents and technology.  The testing used depends 
on the availability of reagents.
 1. First test by hemagglutination using a licensed 
reagent; confirm by hemagglutination with a 
second licensed reagent on a second donation.
 2. First test by hemagglutination using an unlicensed 
reagent because no licensed reagent is available; 
confirm by hemagglutination with a second un-
licensed reagent (or with the same one, if that is 
all that is available) or confirm with unlicensed 
BeadChip, both on a second donation.
 3. First test by BeadChip unlicensed when there 
is limited or no reagent available; confirm with 
licensed reagent on same donation if possible. 
Test subsequent donation with BeadChip assay.
Possible handling of results
Table 4 describes an algorithm also used at the 
NYBC for when the component as antigen-negative 
and addresses when to link the results to the donor’s 
record.  This table takes into consideration the al-
gorithm above for effective use of reagents and will 
only link results to the donor when two different do-
nations have been tested with the same results.  The 
table demonstrates that a donation may be labeled 
with an antigen-negative attribute as long as that do-
nation has been tested with a licensed reagent.  Once 
a second donation from the same donor is tested and 
confirmed to be antigen-negative, additional testing 




As with all new technologies a training and com-
petency program must be adhered to.  The vendor 
should be included in this endeavor.  It is the respon-
sibility of the director of the laboratory, and not of 
the vendor, to ensure results are accurate.
BioArray Solutions offers a 4-day training pro-
gram.  Trainees are given a panel with known results 
to test, and they receive a certificate of competency 
on completion.  As with any laboratory testing, staff 
competency testing must be repeated in 6 months 
and then annually.
Maintenance of test results
The automation of molecular testing generates an 
abundant amount of information.  Great consider-
ation must go into how to manage the results.  NYBC 
has developed a computer program that searches 
for results by chip name, carrier ID, or date.  Any 
combination of antigen results may be chosen to find 
components or donors of interest.  The program is 
able to identify new negative results and provide 
Table 4. Algorithm for donor testing and component labeling
 No. of times 
 tested Donation Label Linked 
Test for Ag tested component to donor
Licensed available 1st 1 Yes No
Confirm with licensed 2nd 2 Yes Yes
Unlicensed/license 1st 1 Yes No 
not available
Unlicensed/license 2nd 2 Yes Yes 
not available
Unlicensed available 1st 1 No No
Confirm with licensed 2nd 1 Yes No
Confirm with licensed 3rd 2 Yes Yes 
or unlicensed
Table 3. FDA classification of procedures
 Investigation use Research use only 
Licensed reagents only (IUO) (RUO)
Hemagglutination Hemagglutination Hemagglutination
 LDT* DNA tests LDT DNA tests
  Microarrays
Approved for clinical  Restricted clinical use Not the sole test for 
use Not the sole test for clinical use 
 clinical use
*LDT = laboratory-developed test.
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the location of retention tubes for ease of retrieval; 
these tubes are then tested serologically to confirm 
the molecular prediction.  In addition, it gives the 
user the capability to review and override results to 
ensure proper use of the information.  NYBC has 
additional software that assists the user in avoiding 
the release of incompatible blood.
If a patient is found to have a clinically significant 
antibody, a test result may be entered into the blood 
bank system for that patient.  As a consequence of 
the test result, the software prohibits the distribution 
of an incompatible blood component to the patient.
If a blood component is requested for a patient 
that has not been tested by the blood center, the order 
entry may include a specific phenotype.  If units are 
selected that do not match the requested phenotype, 
the order cannot be filled and prompts the user.
Patient Care and Component Availability
To maintain an adequate inventory of antigen-
negative RBC components, NYBC currently screens 
the following donor samples per week.  The program 
previously described provides us with a means by 
which to select samples from donors who have not 
been previously tested for these antigens.  By hemag-
glutination, we screen approximately 600 group O 
and group A donor samples in total for 11 antigens 
(C, c, E, e, K, Fya, Fyb, Jka, Jkb, S, s) for “common” 
combinations and more than 200 donor samples for 
15 high-prevalence antigens (U, hrB, hrS, Rh17, k, Kpb, 
Jsb, Yta, Gya, Hy, Joa, Ge, PP1Pk, Vel, Lan). By PCR-
based assays, we screen approximately 10 samples 
by LDT for V, VS, hrB, hrS, Doa, Dob, Hy, and Joa, and 
approximately 90 by HEA BeadChip per week.
With this amount of screening, we can fill the 
majority of requests for antigen-negative RBC 
components.  See Figure 1 for distribution of antigen-
negative RBC components.  However, there are still 
occasions when an order can only be partially filled 
and discussion with the patient’s physician is neces-
sary.  New ways of testing patients and donors with 
the strategies discussed in this paper should allow 
for increased component availability and subsequent 
improved patient care.
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DNA analysis for the prediction of RBC phenotype has broad 
implication in transfusion medicine.  Hemagglutination testing, 
long the gold standard for immunohematology testing, has 
significant limitations.  DNA analysis affords a useful addition 
to the arsenal of methods used to resolve complex serologic 
investigations.  This report discusses the interpretation of 
results obtained by DNA analyses and their correlation with se-
rologic results.  Some current applications to resolve serologic 
problems encountered in patient testing are reviewed and case 
studies are presented to demonstrate the power of combining 
DNA analysis with hemagglutination.  Immunohematology 
2008;24:180–190.
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The primary goal of patient testing performed in 
immunohematology laboratories is the facilitation of 
safe blood transfusions.  Traditionally, hemagglutina-
tion-based methods have been used for this purpose 
as well as for routine tests including antibody iden-
tification and antigen typing of patients and donors. 
Hemagglutination requires the use of specific anti-
bodies that are human source polyclonal antibodies 
or human or murine source monoclonal antibodies. 
Hemagglutination is simple, quick, and relatively 
inexpensive, and when carried out correctly has a 
specificity and sensitivity that is appropriate for most 
testing.  However, hemagglutination, which is a sub-
jective test, has limitations: it can be difficult to type 
RBCs that are coated with IgG or those from patients 
who have been recently transfused; it gives only an 
indirect indication of hemolytic disease of the fetus 
and newborn (HDFN) and cannot reliably determine 
zygosity of, for example, RHD.  Furthermore, hemag-
glutination requires the availability of specific, potent 
antibodies, but licensed reagents are often limited 
in volume, extremely expensive, or not available. 
Finally, some antibodies are only weakly reactive, 
making it difficult to type patients or donors by 
hemagglutination.
The genes of all but one of the blood group 
systems (P awaits definition) have been cloned and 
sequenced, and the molecular bases of most blood 
group antigens and phenotypes have been defined. 
Therefore, DNA-based analyses can be used in the 
clinical laboratory to overcome the limitations of 
hemagglutination and to improve patient care.  The 
purpose of this report is to illustrate the value of 
DNA-based assays for patient testing, to familiarize 
the reader with the interpretation of results obtained 
from such assays, to correlate them with serology, 
and to discuss discrepancies that may be observed 
between genotype and phenotype.
DNA-Based Assays to Predict Presence or 
Absence of Red Cell Antigens
Numerous genetic mechanisms generate blood 
group antigens and phenotypes; these are outlined 
by Reid.1  Most antigens and phenotypes result from 
a single nucleotide change, and simple DNA-based 
assays can be used to predict the presence or absence 
of antigens on RBCs.  A major advantage of DNA-
based assays is that special antisera are not required 
and that the materials for the assays are not from 
human sources but can be readily purchased.
Hemagglutination is performed on RBCs and 
plasma or serum.  Mature RBCs no longer contain 
a nucleus and thus cannot be used as a source of 
DNA.  Suitable sources of genomic DNA are WBCs 
harvested from peripheral blood samples, a buccal 
smear, or urine sediment.
Fundamental to DNA-based assays is PCR ampli-
fication.  This in-vitro method is used to replicate (or 
amplify) a particular piece (or sequence) of DNA (the 
target sequence).  The amplified DNA sequence (am-
plicon) can then be analyzed by a variety of manual, 
semiautomated, or automated methods including 
allele-specific PCR, PCR-restriction fragment length 
polymorphism (RFLP), multiplex assays, real-time 
PCR, and microarray technology.  The end point 
of most manual assays is visualization of the PCR 
product in a gel system after electrophoresis.  With 
automated methods (e.g., microarray technology) the 
PCR products are labeled with fluorescent dyes, and 
the fluorescence intensity is translated by computer 
software to identify alleles and determine genotype. 
These methods are described in detail by Hue-Roye 
and Vege.2
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Interpretation of Results
Hemagglutination-based testing determines the 
presence or absence of an antigen directly through 
agglutination, or lack thereof, when antibody and 
RBCs are combined.  Reagent variability and varia-
tion in strength of antigen expression can confound 
the interpretation of results, particularly those that 
are weak.  Interpretation can be subjective, and a 
reaction considered weak by one technologist may 
be considered to be negative by another.  DNA-based 
assays test for the presence or absence of a nucleo-
tide or a sequence of nucleotides within a gene and 
thus are an indirect method of predicting the likely 
presence or absence of an antigen.  Such assays are 
but a snapshot of a gene at a single location, and 
although referred to as genotyping, the tests sample 
only a small portion of any gene.
Silenced or Non-expressed Genes
A single DNA-based assay may not always be suf-
ficient.  Although a gene may be detected, there are 
times when the gene product is not expressed on the 
RBCs because of the presence of a mutation that si-
lences the gene.  If a grossly normal gene is detected 
in a patient but the gene is not expressed, the patient 
could produce an antibody if antigen-positive blood 
is transfused.  To avoid misinterpretation, when fea-
sible, routine assays must include appropriate tests 
to detect a change that silences gene expression.  For 
example, in the Duffy blood group system, a single 
nucleotide change (–33t>c) within the promoter re-
gion (GATA box) of FY prevents transcription of FY*A 
or FY*B in RBCs but not in other tissues.3  Although 
it is rare to find silencing of FY*A, silencing of FY*B 
is frequent in some populations.  For example, in 
persons of African descent, homozygosity of the 
–33t>c change in FY*B results in the Fy(a–b–) phe-
notype that has a prevalence of 60 percent or higher 
in this population.3  When the assay is to predict the 
presence or absence of D, particularly in populations 
of African descent, it is essential to include a test for 
the RHD pseudogene that, when present, prevents 
expression of D on the RBC surface.4  If the assay 
is for GYPB*S (S antigen), additional testing must be 
performed to detect a C>T change at nucleotide 230 
in GYP*B exon 5 or a change in intron 5 (+5g>t); 
both changes prevent expression of S on the RBC 
surface.5
Controls for DNA-Based Assays
Like hemagglutination, DNA-based assays require 
the use of control samples.  For manual methods, 
each assay should include control DNA samples 
from persons who are known to be homozygous or 
heterozygous for the allele of interest, but in some 
rare situations, samples that are homozygous for an 
allele may not be available.  In contrast to controls 
for hemagglutination tests, in which the positive 
control is usually selected for the weakest expression 
of the antigen, that is, a single dose of the antigen, 
DNA-based assays include both homozygote and het-
erozygote controls for comparison of band size and 
location.  The controls monitor PCR performance, 
amplification efficiency, and enzyme treatment in the 
case of RFLP analyses.  For automated technology, 
generally, signal intensity of fluorescently labeled 
PCR products is measured by computer software and 
translated into presence or absence of a particular 
allele; the fluorescence intensity is also the basis for 
determining allele zygosity.  The specific controls 
required for the various automated platforms are 
beyond the scope of this article.  However, essential 
to both manual and automated assays is a water con-
trol; this is a blank that contains all reagents except 
DNA, the DNA being replaced by the same volume of 
water.  The water control monitors for contamination 
of the test system by extraneous DNA.
Manual Assays Commonly Used
The assays outlined are those commonly used 
for manual testing of DNA.  Automated platforms, 
more recently developed and summarized by Avent,6 
were not applied to the case studies described and 
are beyond the scope of this discussion.
PCR-RFLP
In hemagglutination, enzymes (mainly proteases) 
are valuable tools.  They are used to cleave amino acid 
sequences within protein molecules to gain insight 
into the nature and location of a particular antigen. 
The enzymes used for DNA analyses are restriction 
endonucleases, that is, they digest or cut nucleic 
acids.  They are commonly referred to as restriction 
enzymes.  There are many restriction enzymes; each 
recognizes a specific sequence of DNA and will cut 
(or cleave) DNA whenever the particular sequence is 
present.
An example of a PCR-RFLP assay, using the re-
striction enzyme BanI, is shown in Figure 1.  An 
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RFLP procedure distinguishes two or more alleles 
by virtue of a restriction enzyme site present in one 
allele but not the other.  The specific bands from the 
test samples are compared against the test controls 
and the DNA ladder.  Further detailed descriptions of 
these assays can be found in this issue.2
Allele-Specific PCR
Allele-specific PCR (AS-PCR) is most often used 
when the nucleotide sequence of interest in either 
allele is not associated with a restriction enzyme 
cleavage site.  Two allele-specific primers that differ 
by a single nucleotide complementary to the nucleo-
tide of interest are used in separate reactions, along 
with a common gene-specific primer (to validate the 
overall assay system).  An internal control is included 
that is designed to always give reactivity.  For the 
allele-specific band, amplification denotes the pres-
ence of an allele and lack of amplification denotes 
the absence of an allele.  For an example of AS-PCR 
see Figure 2 in Hue-Roye and Vege.2
Multiplex PCR
A multiplex assay provides the capability of 
concurrently testing multiple alleles on one sample 
from one person.  From a single reaction tube, which 
contains a master cocktail of multiple primers and 
the test DNA, multiple alleles can be distinguished. 
The PCR product is loaded onto either a polyacryl-
amide or agarose gel, and the various alleles can be 
discriminated by the size (and position in the gel) of 
the bands detected.  Figure 2 shows the results of a 
multiplex PCR assay for RH used in our facility.  This 
RH multiplex PCR assay uses a master mix cocktail 
consisting of five pairs of primers to distinguish five 
different alleles coded by RHD and RHCE.4
Applications of DNA-Based Assays
Because the molecular bases of most blood 
group antigens are known, it is now possible to ap-
ply DNA-based assays to overcome many limitations 
of hemagglutination (Table 1).
Testing of Fetal DNA
The first application of DNA-based assays for the 
prediction of blood group phenotype occurred in 
the prenatal setting and was reported by Bennett et 
al.,7 who tested fetal DNA for the presence of RHD. 
Hemagglutination, including determination of anti-
body titer, provides only an indirect indication of the 
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Fig. 1. PCR-RFLP assay.  Digestion with the restriction enzyme BanI 
will discriminate between two alleles, FY*A and FY*B.  FY*A 
will be cleaved in two positions, resulting in three fragments, 
whereas FY*B will be cleaved in one position, resulting in 
two fragments.  Reactions are run on an 8% polyacrylamide 
gel.  (Lane 1) DNA ladder; (lane 2) uncut DNA in which the 
amplicon is not digested with BanI; (lanes 3–5) PCR products 
digested with BanI.
Fig. 2. Multiplex PCR analysis for RH.  Multiplex reactions through 
the simultaneous amplification of sequences with five pairs 
of primers, run on an 8% polyacrylamide gel.  (Lane 9) DNA 
ladder; (lane 6) water control containing no DNA; (lanes 1–5, 
7, 8) PCR products representing various Rh genotypes.  The 
DNA ladder consists of assorted DNA with a defined number 
of base pairs of DNA and is a basis for comparison of the DNA 
fragments being analyzed.
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risk and severity of anemia or HDFN.  Because of 
the clinical significance of anti-D, RHD is probably 
the most frequent target gene, but DNA-based assays 
can be used to predict the antigen type of the fetus 
for many antigens.  When a fetus is predicted to be 
antigen-negative, the need to aggressively monitor 
the pregnancy, and any associated risk to the fetus, 
is avoided.  When the implicated IgG antibody in the 
maternal circulation is not anti-D, it is still prudent to 
test the fetal DNA for RHD to preempt unnecessary 
requests for D– blood for intrauterine transfusion; 
this is particularly relevant to avoid the use of rare 
r′r′ or r′′r′′ blood when dealing with anti-c or anti-e 
as the implicated antibody.
Most commonly, amniocytes, harvested from am-
niotic fluid, are the source of fetal DNA.  Chorionic 
villus sampling and cordocentesis are not favored 
because of their more invasive nature and associated 
risk to the fetus.  A noninvasive sample source is the 
cell-free fetal DNA that is present in maternal plasma 
as early as 5 weeks of gestation; the amount of DNA 
increases with gestational age, and reliable results in 
DNA-based assays are obtained from about 15 weeks’ 
gestation.  This method has great potential, but be-
cause of patent issues, assays that use cell-free fetal 
DNA currently cannot be used in the United States. 
Regardless of the source of fetal DNA, controls (e.g., Y 
chromosome markers if fetus is male or polymorphic 
paternal markers if female) are essential to ensure 
that fetal, and not maternal, DNA is being tested, 
and systems must be in place to avoid false-negative 
results such as may be caused by low levels of fetal 
DNA.  To aid in the interpretation of results, ideally, 
parental DNA should be tested in parallel.  A more 
detailed discussion of fetal blood group genotyping 
is provided by Denomme and Fernandes.8
DNA-Based Assays to Predict the RBC 
Phenotype of Patients
Patients Whose RBCs Are Coated With IgG (DAT+)
It can be difficult or impossible to type RBCs that 
are coated with IgG and hence react in the direct 
antiglobulin test (DAT).  Methods such as treat-
ment of the RBCs with chloroquine diphosphate or 
EDTA-glycine acid (EGA) may be used to remove the 
RBC-bound IgG.  These methods are not always suc-
cessful, or the antigen of interest may be denatured 
by the treatment (e.g., EGA destroys antigens of the 
Kell blood group system), and direct agglutinating 
or murine monoclonal antibodies for the antigen of 
interest may not be available.  Under these circum-
stances, DNA-based assays are a valuable tool for the 
prediction of the RBC phenotype and can be used to 
overcome the limitations of hemagglutination.
Recently Transfused Patients
For the recently transfused patient, obtaining an 
accurate phenotype can be a challenging and some-
times impossible task.  Attempts to separate transfused 
donor RBCs from those of the patient are often not 
successful, and so the patient’s most probable pheno-
type may be derived by the best-guess method, that 
is, the patient’s phenotype is based on the strength of 
agglutination (in a mixed field reaction), the number 
of RBC components transfused, the time since the 
last transfusion, the estimated blood volume of the 
patient, and the prevalence of the antigen.  Reid et 
al.9 reported that DNA-based assays can be used to 
predict a patient’s phenotype and that transfused do-
nor leukocytes do not affect the result.  They showed 
that the results of analysis of DNA extracted from 
peripheral blood leukocytes, urine sediment, or buc-
cal smear were concordant with those obtained in 
pretransfusion hemagglutination tests, and that the 
best-guess method is unreliable.  In our laboratory 
we frequently receive requests to perform DNA-based 
assays to help in the resolution of transfusion prob-
lems when hemagglutination cannot provide an 
answer.  An example, which demonstrates the value 
of DNA-based assays for patient care, is briefly pre-
sented in Table 2.  Traditionally, when a patient with 
autoimmune hemolytic anemia has been transfused 
before establishing the patient’s RBC phenotype for 
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Table 1. Applications of DNA-based assays for patient testing
Predict the RBC phenotype when
• A patient was recently transfused
• RBCs are coated with IgG (DAT+) and direct agglutinating 
antibodies or murine monoclonal antibodies are not available; or 
when methods to remove IgG coating are unsuccessful
• A fetus is at risk for HDFN
• Antibody is weak or not available, e.g., anti-Doa, anti-Jsa, anti-V
Determine zygosity, particularly RHD
Resolve discrepancies, e.g., A, B, D, C, c, e
Distinguish allo- from autoantibodies
Detect weakly expressed antigens (e.g., Fyb with the FyX phenotype); 
when patient is unlikely to make antibodies to transfused antigen-
positive RBCs
Identify molecular basis of unusual serologic results
Aid in the resolution of complex serologic investigations
184 I M M U N O H E M AT O L O G Y,  V O L U M E  2 4 ,  N U M B E R  4 ,  2 0 0 8
minor antigens, time- and resource-consuming al-
logeneic absorptions will be required to determine 
the presence or absence of alloantibodies underlying 
the autoantibody.  Establishing the patient’s most 
probable phenotype through DNA-based assays will 
allow for matching the antigen profile of the absorb-
ing RBCs to that of the patient, thereby reducing the 
number of cell types required for absorption.
DNA-Based Assays to Aid in the Resolution of 
Complex Serologic Investigations
DNA-based assays are an exciting new tool in 
our arsenal of procedures to use when attempting to 
resolve complex serologic investigations.  A serologic 
investigation can be complex for a number of rea-
sons: it may involve a combination of alloantibody 
and autoantibody, it may involve an antibody to a 
high- or low-prevalence antigen, it may involve an 
antibody to an antigen for which RBC samples on 
antibody identification panels are not typed (e.g., 
Doa, Dob, Hy, Joa), or it may be an investigation that is 
difficult to resolve with standard methods and avail-
able resources.  The next section presents cases that 
were tested (and resolved) in our laboratory because 
of the power of combining hemagglutination with 
DNA-based assays.
tO Distinguish allOantiBODy FrOm autOantiBODy
A sample, with a hemoglobin value of 7.1 g/dL, 
was received from a 65-year-old white female with a 
tumor and a history of anemia.  Three months earlier 
the patient’s antibody screen had been negative, all 
units crossmatched had been compatible, and she 
had been transfused with two RBC units. Serum 
from the current sample reacted with all samples on 
an antibody identification panel.
Patient’s RBCs.  The results of the DAT indicated 
that the patient’s RBCs were coated with IgG (1+ 
reaction with anti-IgG) and the C3 component of 
complement.  When antigen typing was performed 
with monoclonal antibodies, surprisingly her RBCs 
appeared to be K–k–.  There was no evidence for 
the presence of transfused RBCs.  The patient’s 
RBCs were treated with chloroquine diphosphate to 
remove the IgG coating (EGA, because it destroys 
Kell antigens, could not be used) and were found 
to be K–k+w/–, Kp(a+wb+w/–), and Js(b+w/–).  In this 
situation, it was difficult to interpret the significance 
and validity of such findings.
Patient’s Serum.  By the IAT all RBCs, except 
those that were K0 or Kp(b–) or treated with DTT, 
were agglutinated.  This suggested the presence 
of anti-Kpb. It is not unusual for anti-Kpb to be an 
autoantibody and to be associated with the transient 
suppression of Kell antigens on the RBCs of the 
antibody maker.  However, people with a genetic 
Kp(a+b–) phenotype who make alloanti-Kpb can also 
have reduced expression of Kell antigens because of 
the cis-modifier effect of Kpa.  Therefore, the ques-
tion to be answered was whether the antibody in the 
serum of the patient was allo- or autoanti-Kpb.
Eluate Prepared From the Patient’s RBCs.  This 
appeared to contain autoanti-Ku because it reacted 
weakly with Kp(b–) and moderately with Kp(b+) but 
did not react with K0 RBCs.
To gain insight into the cause of the Kell anti-
gen suppression on the patient’s RBCs, PCR-RFLP 
analysis of KEL was performed.  The restriction 
enzyme NlaIII was used for PCR-RFLP analysis of 
KEL*3/KEL*4 (Kpa/Kpb) and revealed apparent homo-
zygosity for nucleotide 961T, in exon 8 of KEL.  No 
other changes in the patient’s KEL genes were found. 
Based on this result, the patient’s RBCs are predicted 
to be Kp(a+b–) and the anti-Kpb in her serum is 
most likely alloantibody.  The reduced expression 
of Kell antigens on her RBCs can be attributed to 
the cis-modifier effect of Kpa and not to temporary 
antigen suppression associated with autoantibody 
formation.
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Table 2. Case study to demonstrate the value of DNA-based assays 
to predict the RBC phenotype in the care of chronically or 
recently transfused patients
A 59-year-old female with autoimmune hemolytic anemia and a history 
of chronic transfusion had made anti-E and anti-K.  All E– K– RBC 
units are incompatible.
The patient’s RBC phenotype could not be determined by 
hemagglutination.
No additional alloantibodies were demonstrated by repeated allogeneic 
adsorptions with R1R1, R2R2, and rr RBCs performed at the referring 
laboratory; however, the patient consistently has overt posttransfusion 
hemolysis.
Patient’s sample was submitted for DNA-based assays.
Her probable genotype was found to be: RHD, RHCE*C/c, RHCE*e/e, 
KEL*2/2, JK*A/A, GYPB*S/s, FY*A/B (with a wild-type GATA box).
Her most likely predicted RBC phenotype is:  D+C+E–c+e+, K–k+, 
Jk(a+b–), S+s+, Fy(a+b+).
In addition to being E– and K–, the patient’s RBCs are predicted to be 
Jk(b–).
Did alloanti-Jkb cause posttransfusion hemolysis?  Highly likely; patient 
was successfully transfused with E– K– Jk(b–) RBC units without overt 
posttransfusion hemolysis.
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as a tOOl tO aiD in the iDentiFiCatiOn OF a WeaKly 
reaCtive antiBODy tO an antigen FOr WhiCh rBCs 
panel Cell samples are nOt typeD
A 73-year-old white male with hemolytic anemia 
(Hb = 8.2 g/dL, Hct = 24.7%) was scheduled for trans-
fusion.  His plasma was known to contain anti-c and 
-E, and he had been transfused with two c– E– RBC 
units 1 month earlier.  RBCs from his current sample 
did not react in the direct antiglobulin test, and al-
most no mixed-field agglutination was observed.  His 
plasma was now incompatible with all c– E– units, 
but the autologous control was negative.  Anti-k was 
identified in his plasma.  However, additional very 
weak reactions were observed with two examples 
of phenotype-matched K+k– panel cells (one sample 
reacted by PEG IAT, the other, which was pretreated 
with papain, also reacted by the IAT).  It was dif-
ficult to interpret the significance of these reactions, 
but both of the reactive panel cells were Do(a+) 
whereas some of the nonreactive ones were known 
to be Do(a–), and the possibility that the patient had 
also made anti-Doa was investigated.  Because most 
examples of anti-Doa and anti-Dob are weakly reac-
tive, available in small volume, and usually found 
in plasma containing other alloantibodies (as well 
as needing to overcome ABO incompatibility), and 
because the patient was transfused, DNA-based 
analysis was favored over hemagglutination.  DNA 
was extracted from a peripheral blood sample from 
the patient, analyzed for DO*A and DO*B, and found 
to be DO*B/DO*B.  Thus, the patient’s RBCs would 
be predicted to be Do(a–b+).  To determine the pres-
ence or absence of anti-Doa in plasma that contains 
anti-k (and anti-c and anti-E) can be a daunting task, 
but fortified by the knowledge that the patient at 
least had the potential to make anti-Doa, the investi-
gation was continued.  Few k– RBC samples, typed 
for Doa and Dob, were available, and the reactions 
observed with Do(a+) RBCs were too weak to be 
reliable; therefore, the patient’s plasma was adsorbed 
onto a reactive Do(a+), k–, c–, E– RBC sample.  An 
acid eluate prepared from the sensitized RBCs was 
nonreactive by PEG IAT but was shown to contain 
anti-Doa by testing papain-treated Do(a+b–) RBCs 
by the IAT; RBCs expressing a single dose of Doa 
(Do[a+b+]) did not react.
Anti-Doa and anti-Dob, although generally weakly 
reactive, are clinically significant, and antigen-nega-
tive blood should be used for transfusion.  In the 
past, the scarcity of potent antibodies and lack of lic-
ensed reagents with anti-Doa (or anti-Dob) specificity 
forced reliance on the crossmatch to select units suit-
able for transfusion in similar situations.  The advent 
of DNA-based assays has made it possible to test 
selected antigen-negative donors (in this case, those 
that are k–, c–, E–) for DO*A and DO*B and provide 
donor units that are predicted to lack the offending 
antigen.  Such applications have demonstrated that 
testing DNA for the Doa/Dob polymorphism (and 
for changes associated with a lack of Dombrock 
high-prevalence antigens) clearly surpasses hemag-
glutination for antigen determination.10
as a tOOl tO aiD an investigatiOn that is DiFFiCult 
tO resOlve With stanDarD methODs anD availaBle 
resOurCes
A sample from a 72-year-old Italian woman was 
received for antibody identification.  The patient had 
presented in the emergency room feeling dizzy and 
unwell.  Ten days earlier she had undergone coronary 
artery bypass graft surgery.  Although the patient 
had a history of three pregnancies, in preoperative 
tests the antibody screen was negative and all units 
were crossmatch compatible.  She received four units 
of RBCs during surgery, and at the time of her arrival 
in the emergency room her hemoglobin was 7.2 g/dL 
and all RBC units were incompatible when cross-
matched with her serum.  Surprisingly, the results of 
antigen typing of her RBCs suggested an absence of 
transfused RBCs in her circulation.
Testing of the patient’s serum indicated the 
presence of an antibody directed at a high-preva-
lence antigen that was resistant to treatment with 
papain, trypsin, α-chymotrypsin, and DTT.  RBCs 
lacking high-prevalence antigens that matched this 
profile were tested with her serum, and all, includ-
ing Wr(a+b–) RBCs, reacted strongly.  However, 
ENEP– and ENAV– RBCs were only weakly reactive, 
and RBCs with the MkMk, GP.Hil/GP.Hil (Mi.V/Mi.V), 
and GP.JL/Mk (Mi.XI/Mk) phenotypes and her own 
RBCs did not react.  These findings indicated that 
the antibody detected an antigen related to the 
MNS blood group system, but testing for the known 
high-prevalence MNS antigens did not reveal the 
specificity.  As the antigen was resistant to treatment 
with papain, trypsin, and α-chymotrypsin, its most 
likely location on glycophorin A (GPA) was close to 
the RBC membrane (Fig. 3).
The patient’s RBCs were M+N–, S+s–, and Wr(a–) 
and found to be Wr(b+w) when tested with eight 
examples of monoclonal anti-Wrb.  This altered ex-
pression of Wrb was consistent with the possibility 
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that the antigen was located on GPA close to the 
RBC membrane, because expression of Wrb, which 
is carried on band 3 and is an antigen of the Diego 
blood group system, is dependent on the interaction 
between band 3 and amino acid residues 59 to 76 of 
GPA.
GYPA encodes GPA and exon 4 of GYPA encodes 
the portion of GPA closest to the RBC membrane; 
therefore, DNA sequencing of exon 4 was per-
formed.  A change of T>G at nucleotide 242 was 
identified; this would be predicted to result in a 
Val62Gly amino acid change in GPA.  In that case 
the antibody made by the patient detects an anti-
gen, which was named ENEV (MNS45) by the ISBT 
Terminology Committee,11,12 that requires valine at 
residue 62 to be expressed.  The predicted location 
of ENEV on GPA is close to that of ENEP and ENAV 
(Fig. 3), and so it is not surprising that the anti-ENEV 
in the patient’s serum gave weaker reactions with 
ENEP– and ENAV– RBCs.  The weakened expression 
of Wrb on the patient’s RBCs can also be explained 
by the Val62Gly change as it is within the sequence 
of amino acids (residues 59 to 76) that interacts with 
band 3 to form Wrb.
The 242T>G change ablates a DNA cleavage 
site for the restriction enzyme RsaI.  This allows for 
the development of a PCR-RFLP assay that not only 
can be used to confirm that the patient is indeed 
homozygous for nucleotide 242G but also can be 
used in place of DNA sequencing to identify other 
patients who may lack this high-prevalence antigen 
and as a screening tool (in the absence of serum) 
to look for potential ENEV– donors, as the clinical 
significance of anti-ENEV was clearly demonstrated 
by this patient.
as a tOOl tO iDentiFy antiBODies DeteCting CrOmer 
BlOOD grOup system antigens
The Cromer blood group system currently con-
tains 12 antigens of high prevalence and 3 antigens 
of low prevalence; they are carried on the comple-
ment protein decay-accelerating factor (DAF; CD55). 
Antibodies directed at the various Cromer antigens 
and RBCs expressing Cromer phenotypes are gener-
ally not readily available.  Those that are available 
are not necessarily of the ABO type appropriate for 
the sample being investigated.  Five new antigens, 
all of high prevalence, were assigned to the Cromer 
blood group system in recent years with relative ease 
(by comparison to some of the earlier antigens) by 
combining hemagglutination and DNA-based as-
says.  To demonstrate the power of this combined 
approach, the investigation that identified the CRAM 
antigen, the most recent to be assigned to Cromer, is 
outlined here.13
During the third pregnancy of a Somali woman 
who had never been transfused, her serum was found 
to react with all panel cells tested, but it did not react 
with her own RBCs.  The characteristics of the anti-
body in the initial hemagglutination testing (Table 3) 
indicated that the antibody was most likely directed 
at an antigen in the Cromer blood group system.  The 
woman’s RBCs were Cr(a+), Tc(a+), Dr(a+), WES(b+), 
Es(a+), UMC+W, IFC+, GUTI+, SERF+, ZENA+, and 
CROV+ and all of the known Cromer high-prevalence 
antigens were ruled out.  The only remarkable find-
ing was that the expression of UMC on her RBCs was 
much weaker than that on the positive control.
The Cromer antigens are carried on one of four 
regions of the DAF molecule referred to as short 
consensus repeat (SCR) regions (or complement 
control protein, CCP) that are encoded by exons 2 
to 6 of DAF.  DNA that had been extracted from a 
peripheral blood sample from the woman was ana-
lyzed.  Regions of DNA that included exons 2 to 6 
Fig. 3. Diagram of glycophorin A (GPA) and glycophorin B (GPB). 
Shown are the cleavage sites for proteases and the area on 
GPA that interacts with band 3 (Diego) for expression of Wrb. 
Also shown is the location of ENEV (MNS45) on GPA.  ENEV 
(62) is one amino acid from ENAV (63) and three from ENEP 
(65), which explains the weakened reactivity of the patient’s 
serum with ENEP– and ENAV– RBCs.
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and the flanking regions of DAF were amplified and 
sequenced, and a nucleotide change (740A>G) was 
identified in exon 6.  This change was predicted to 
encode an amino acid change, Gln247Arg, in SCR4 of 
DAF (Fig. 4).  Thus, DNA analyses quickly revealed 
the molecular basis of the antigen detected by the 
antibody in the patient’s serum and confirmed, by 
locating the antigen on DAF, that the antibody was 
indeed directed at an antigen of the Cromer blood 
group system.  The scarce quantities of rare RBCs 
and sera were conserved so as to be available for 
other investigations.  In our laboratory, if the initial 
findings of an investigation indicate an antibody to 
a Cromer system antigen (based on the characteris-
tics in Table 3), serologic testing is halted and DNA 
analyses are performed on the sample.  Any findings 
are then confirmed serologically, providing suitable 
serum and cell samples are available.
Resolving Discrepancies
The reactivity of reagents from different manufac-
turers with the same antibody specificity, for example 
anti-D, may differ when tested with RBCs expressing 
unusual phenotypes, such as weak or partial D.  This 
can cause results that appear discrepant when anti-
gen typing is performed by different facilities or even 
by the same facility when a different reagent is in 
use.  With the use of DNA-based assays, it is possible 
to show that a typing discrepancy is attributable to 
a genetic variant rather than technologist error or 
reagent failure that could be reportable to the Food 
and Drug Administration.
ABO Discrepancies
From the standpoint of hemagglutination test-
ing, the ABO system is very simple.  At the DNA 
level, however, there is tremendous complexity and 
diversity, and for each phenotype many different 
genotypes have been identified.  For this reason, 
it would not be practical to perform routine ABO 
typing by DNA analysis; it is, however, an extremely 
valuable tool for the resolution of typing discrepan-
cies.  It allows, for example, the distinction between 
an acquired phenotype and one that is inherited, 
such as acquired B phenotype or ABO antigen loss 
as a result of leukemia or malignancy.
Distinction between Weak D and a Partial D 
Phenotype
D is second only to the ABO antigens in clini-
cal significance.  Many D variant alleles have been 
defined at the molecular level.14–17  Of particular 
importance from a clinical standpoint is the ability 
to distinguish a weak D from a partial D phenotype. 
An individual with a partial D phenotype can make 
an alloanti-D, whereas individuals with a weak D 
Table 3. Characteristics of antibodies to high-prevalence Cromer 
antigens demonstrated by the antibody in the patient’s serum
Reactive with all RBCs except autologous
Reactive with RBCs pretreated with ficin, papain, or trypsin
Nonreactive with RBCs pretreated with α-chymotrypsin
Weakly reactive with RBCs pretreated with 200 mM DTT; reactive with 
RBCs pretreated with 50 mM DTT
Nonreactive with Inab (Cromer null) phenotype RBCs
Weakly reactive with Dr(a–) RBCs
Nonreactive with PNH III RBCs
Detect antigens carried on decay-accelerating factor (DAF; CD55)
Fig. 4. Location of Cromer antigens on DAF.  The amino acid associated 
with CRAM (residue 247) is, in the primary sequence of 
DAF, located between that for ZENA (residue 242) and UMC 
(residue 250).  The change at residue 247 could explain the 
weakened expression of UMC on CRAM– RBCs.
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phenotype do not.  It is often difficult to differentiate 
these phenotypes serologically.
Determination of Rh Phenotypes That Cannot be 
Easily Distinguished by Serology
Similarly, there are many other Rh phenotypes 
that are difficult to distinguish or even define purely 
by serologic methods.  The use of DNA-based assays 
facilitates the definition of many D and e variant 
antigens.  For patients who require chronic transfu-
sion support, such as those with sickle cell disease, 
and whose RBCs express an unusual Rh phenotype, 
RBC transfusions can pose a challenge once the pa-
tient becomes alloimmunized.  To provide ongoing 
transfusion support for these patients, the hope is to 
be able to precisely match donor and patient at the 
genotype level.  It is difficult, for example, because 
of a lack of potent, monospecific antisera, to type 
patients and donors for hrS.  Several genotypes have 
been associated with the hrS– phenotype, and the 
use of DNA-based assays may provide a better match 
between patient and donor than would hemaggluti-
nation.  (This is discussed in detail, with reference to 
Rh, by Westhoff in this issue.18)
Weak Expression of an Antigen
DNA analysis is useful for the detection of weakly 
expressed antigens.  For example, a patient with the 
FyX phenotype (FY*A/FY*X) and a greatly reduced 
expression of the Fyb antigen, caused by a change at 
nucleotide 265, at the FY*B locus, is unlikely to make 
anti-Fyb if transfused with Fy(b+) RBCs.19  In this 
situation, DNA analysis can help determine which 
phenotypically antigen-negative patients can safely 
receive antigen-positive RBCs.  The weakened Fyb 
antigen attributable to the FyX phenotype is difficult 
to detect serologically with most commercial anti-Fyb 
reagents.  Occasionally, a reagent that detects the Fyb 
of FyX is available.  Using one of them can cause 
discrepancies with historical phenotypes.  In such a 
situation DNA analysis is the more definitive assay.
Limitations of DNA-Based Assays
Correlation with Hemagglutination
Many genetic events, such as the silencing of genes 
discussed earlier, can cause apparent discrepancies 
between the results obtained by DNA analyses and 
those obtained by hemagglutination; some examples 
are shown in Table 4.20–22
Clinical Situations
DNA and hemagglutination test results may not 
agree in certain clinical situations that include recent 
transfusion, allogeneic stem cell transplant, and 
natural chimerism.  Allogeneic stem cell transplant 
and natural chimerism may also cause the results 
of testing DNA from somatic cells (such as those 
obtained from a buccal smear) to differ from those 
of testing DNA from peripheral WBCs.  When DNA-
based assays are applied to the fetal-maternal setting, 
discrepancies may be observed if the fetal sample is 
contaminated with maternal DNA, if the mother is 
a surrogate, or if the fetus is the result of artificial 
insemination.  Therefore, it is extremely important to 
obtain an accurate medical history for the patient.
Null Phenotypes
Null phenotypes for most blood group systems 
pose challenges for DNA-based assays.  Multiple 
molecular bases have been identified for most null 
phenotypes, for example, Rhnull, K0, Gy(a–), and 
Jk(a–b–).  The identification of these null phenotypes 
by simple DNA-based assays sampling one nucleo-
tide is not feasible.  Several locations on a gene 
would need to be analyzed, and for the detection of 
most null phenotypes, hemagglutination is the test 
of choice.  The majority of DNA-based assays will 
detect a grossly normal gene that is not expressed, 
and this can lead to a donor or patient being falsely 
identified as antigen-positive.  In the case of a donor 
this would mean that a valuable antigen-negative 
(e.g., null) donor would be lost to the inventory, but 
such an occurrence would not jeopardize the safety 
of a patient receiving blood transfusion.
Conclusions
DNA analysis is an exciting new approach and a 
valuable tool to resolve problems in the immunohe-
matology laboratory.  But, just as hemagglutination 
has limitations, so do DNA-based assays.  Some 
Table 4. Examples of apparent discrepancies between DNA analysis 
and hemagglutination
Genetic Event RBC Phenotype
Premature stop codon D–, K0, Rhnull
Insertion of nucleotides Co(a–b–)
Gene rearrangement  Many phenotypes in the Rh and MNS 
system, e.g., D–, DVa, Mi(a+), Vw+
Presence of modifying gene Jk(a–b–), Lu(a–b–)
Altered splice site Jk(a–b–), Gy(a–)
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limitations that were mentioned earlier in this paper 
are worthy of reiteration.  A most important point 
to remember is that a genotype is not a phenotype, 
and there are circumstances when the allele detected 
at the DNA level will not be reflected by the antigen 
expressed on the RBC.  More than one genotype can 
give rise to the same phenotype; this is especially so 
with the null phenotypes.  When feasible, appropri-
ate assays that detect changes that silence a gene 
should be performed.  Hemagglutination testing still 
remains the method of choice in circumstances when 
the molecular basis is unknown or when multiple 
molecular bases exist for a particular phenotype, 
especially with null phenotypes.  In certain situa-
tions, particularly if DNA-based analyses are used to 
screen donors, it is recommended that antigen-nega-
tive results be confirmed by hemagglutination using 
a licensed reagent when available or by crossmatch-
ing.  This approach conserves expensive and rare 
reagents.
As discussed in this paper, hemagglutination 
and DNA analysis are each powerful tools in their 
own right, but each technology has certain inherent 
limitations.  Their joint potential is immense when 
one becomes an adjunct for the other and they are 
jointly applied to resolve complex antibody problems 
and facilitate safe blood transfusion.
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The potential of blood 




Molecular diagnostics is the fastest growing area of clinical 
laboratory medicine.  The ability to rapidly amplify genes 
of bacterial, viral, or human origin, and the development of 
DNA array platforms, are driving a technology revolution 
in the clinical laboratory.  A DNA-based testing approach is 
particularly applicable to blood bank and transfusion medi-
cine for rapid, cost-effective antigen typing.  Experience with 
DNA-based methods during the past decade has shown that 
these assays are reproducible and highly correlated with the 
RBC phenotype.  The recent availability of automated, high-
throughput, DNA-array platforms now moves testing from the 
reference laboratory setting into hospital and donor testing 
centers.  This approach has the potential to revolutionize the 
process of locating antigen-negative donor units by testing for 
all clinically significant blood group antigens in a single assay. 
When partnered with the same extended typing of the patient, 
electronic selection of units antigen-matched at multiple blood 
group loci is then possible.  This paper discusses the potential 
of this approach to improve transfusion therapy by reducing or 
eliminating alloantibody production in specific patient popu-
lations.  These include patients facing long-term transfusion 
therapy and at high risk for sensitization; patients with warm 
autoantibodies when compatibility cannot be demonstrated by 
standard methods; and women for whom the production of 
atypical antibodies carries a risk for hemolytic disease of the 
fetus and newborn, or at the very least, monitoring for an at-
risk pregnancy.  Immunohematology 2008;24:190–195.
Key words: blood groups, DNA testing, molecular 
testing, transfusion practice, Rh molecular testing
Molecular diagnostics is revolutionizing the field 
of clinical laboratory testing.  The ability to rapidly 
amplify genes by PCR, along with the development of 
high-throughput platforms and automated interpre-
tation, is driving a technology revolution in disease 
and cancer diagnosis, coagulation therapy, molecular 
pathology, and microbe identification.  DNA-based 
test methods are especially applicable to blood 
bank and transfusion medicine because the genes 
encoding blood group antigens are known, and the 
genetic polymorphisms associated with the antigens 
have been determined.  Many blood group antigens 
result from single-nucleotide polymorphisms (SNP) 
that follow Mendelian inheritance, and the test meth-
ods target blood group genes to predict the RBC 
phenotype.
In the past decade, molecular testing has been 
limited primarily to reference laboratory environ-
ments.  The manual test methods and assays are 
labor intensive, and discrepancies require exten-
sive serologic and molecular genetic investigation. 
Significant progress has been made in validating the 
gene targets and investigating and explaining dis-
crepancies between the phenotype, determined with 
RBCs and antibody reagents, and the genotype, de-
termined with DNA and oligonucleotide primers. 
Assays that target allelic polymorphisms prevalent in 
all populations are reproducible and highly correlat-
ed with RBC phenotype.1  For some blood groups, 
detection of common silencing mutations is also re-
quired for accurate typing.  Key examples include 
the GATA mutation that silences Fyb expression on 
RBCs,2 and the two GYPB changes that silence gly-
cophorin B (Ss antigen) expression.3  For ABO and D, 
numerous polymorphisms are involved in antigen ex-
pression, and multiple regions of the genes must be 
sampled for accurate interpretation.  Hence, aggluti-
nation will remain the method of choice for routine 
ABO and D typing for the near future.  DNA anal-
ysis is a powerful adjunct to serologic testing, and 
specific applications for typing multiply transfused 
patients, typing antigens for which serologic reagents 
are not available, determining zygosity, testing fetal 
DNA, detecting weak expression of an antigen, dis-
tinguishing alloantibodies from autoantibodies, and 
resolving reagent typing discrepancies are discussed 
in the paper by Lomas-Francis and DePalma in this 
issue.4
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The development of automated, high-throughput 
testing platforms now moves testing into the main-
stream because it allows for screening of markers 
associated with all major antigens in a single assay 
without complex testing, high-level technical skills, 
or subjective interpretation.5–8  Although not FDA li-
censed for labeling the donor unit, these platforms 
are a valuable screening tool to identify units nega-
tive for multiple antigens.  The absence of specific 
antigens can then be confirmed with licensed typing 
reagents, and the unit can be labeled, significantly 
reducing the number of serologic typing reactions 
and the labor and reagents required to identify units 
of interest.  Some rare units lacking high-prevalence 
antigens can also be identified, depending on the 
gene targets included on the platform design.  High-
throughput molecular screening will significantly 
impact the process of providing antigen-negative 
and rare donor units and is further discussed by 
Strauss and Reid in this issue.9
When partnered with testing of the patient sam-
ple, molecular screening of donors has the potential 
to improve transfusion therapy.  Knowledge of the 
extended phenotype of the units in the donor or 
hospital inventory, when partnered with screening 
of the patient, presents an exciting opportunity to 
provide an RBC component more precisely matched 
at multiple blood group loci.  This approach could 




Statistical analysis suggests that, overall, approxi-
mately 13 percent of patients are at risk of forming 
alloantibodies.10  However, patients with sickle cell 
anemia have an increased risk, primarily because of 
the large number of donor exposures and the genetic 
disparity between patients of African Black ancestry 
and Caucasian blood donors.  Additionally, patients 
who have made one alloantibody, indicating they are 
responders, are at increased risk for production of 
additional antibodies.11
The presence of blood group antibodies compli-
cates transfusion in emergency situations and adds 
complexity and cost to blood bank laboratory work-
ups.  Fortunately, serious or fatal complications are 
not frequent, and production of RBC antibodies has 
been considered a manageable risk of transfusion. 
Alloantibodies can be of more serious consequence 
in some situations, particularly for patients with 
sickle cell disease and for pregnant women.  Patients 
with sickle cell disease have compromised RBC 
survival and are anemic, so hemolysis as a result 
of an alloantibody could cause serious anemia and 
trigger a sickle cell crisis.  Complications caused by 
alloantibodies in pregnant women can range from 
serious or fatal hemolytic disease of the fetus and 
newborn (HDFN) or, at a minimum, costly monitor-
ing for a high-risk pregnancy.  Table 1 lists patient 
populations for which alloantibodies are potentially 
of greater consequence.
Prevention
The ultimate goal to advance the practice of 
transfusion medicine would be to prevent alloim-
munization, realizing that prevention may not be 
possible for all patients because of the large num-
ber of antigens (302 are known)12 and inventory 
limitations, i.e., the number of donor phenotypes 
in inventory that potentially match the recipient. 
Because not all antigens are clinically significant or 
strongly immunogenic, an approach that focuses on 
the five primary systems, Rh (CcEe), Kell, Kidd (Jka/
b), Duffy (Fya/b) and Ss, partnered with one that pri-
oritizes patients according to alloimmunization risk, 
would be a first approach to prevention (Table 1). 
Studies to determine the degree of antigen disparity 
between donors and patients is needed.  The data 
may differ significantly between geographic regions 
of the country, and the success of donor recruitment 
efforts in minority communities would impact the 
results. It is now possible to gather a large amount of 
information about the degree of antigen concordance 
in a community with automated genotyping.  This 
information is the key for discussions about future 
possibilities for extended matching.
Table 1. Patient categories for which alloantibodies are potentially of 
greater consequence
Category Antigen target for extended match
Patient with sickle cell disease C, E, K 
(prophylactic transfusion) altered C, partial D, partial e 
 Fya, Jka, Jkb, S, s
Patient with warm  C, c, E, e, K 
autoantibodies Jka, Jkb, Fya, Fyb, S, s
Patient with alloantibody(ies) C, c, E, e, K 
 Jka, Jkb, Fya, Fyb, S, s
Women of childbearing age  D, K, c 
and female children
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Patients with Sickle Cell Disease
Antibody production is a serious complication 
in patients with sickle cell disease (SCD) on long-
term transfusion therapy.  From 33 to 60 percent of 
chronically transfused patients with SCD become im-
munized, and transfusion is further complicated by 
the presence of multiple alloantibodies in as many as 
45 percent of patients.11  Alloimmunization can have 
severe clinical consequences, not only because there 
can be significant delays in finding compatible blood, 
but also because alloimmunization is associated with 
delayed hemolytic transfusion reactions (DHTR), 
autoantibody formation, and hyperhemolysis syn-
drome.  Indeed, RBC autoantibody production is 
increasingly recognized as a serious problem con-
current with alloantibody formation, with a reported 
incidence of 8 to 42 percent (reviewed by Smith-
Whitley13).  The clinical significance of autoantibodies 
becomes secondary in the effort to honor the specific 
alloantibodies present, and patients receive “incom-
patible” blood.  This is not an ideal scenario for a 
patient population in which the benefit is propor-
tional to the longevity of transfused RBCs, and this 
may result despite an extensive laboratory workup 
that consumes significant time and resources.
Management of alloimmunization in SCD has 
been the subject of much debate,14,15 but currently 
there is no standard approach.  Many programs at-
tempt to prevent or reduce the risk and incidence 
of alloantibody production by transfusing RBCs that 
are antigen-matched for D, C, E, and K.  Although 
randomized controlled trials have not been done, this 
approach has been shown in single institutional and 
prospective multicenter experiences to significantly 
reduce the incidence of alloantibody production.16–18 
A 40 to 90 percent reduction was seen, depending 
on the extent of antigen matching (4 to as many 
as 15 antigens), accompanied by decreased DHTRs 
compared with historic rates in SCD patients.
In contrast to prophylactic antigen matching, 
some institutions perform phenotype matching after 
the patient develops the first alloantibody.  Others 
argue that the data supporting a reduction in DHTR/
H are insufficient to offset the cost of the labor and 
resources required to perform extended matching for 
SCD patients.19
Alloimmunization despite antigen matching
Despite antigen matching for D, C, E, and K, some 
patients still become alloimmunized.  The antibodies 
often have multiple and complex specificities in the 
Rh system, and although the patient’s RBCs may type 
serologically as positive for D, C, or e, the antibod-
ies have D, C, or e-like specificities.20  Analysis of 
the RH genes in these patients reveals they encode 
amino acid changes in the Rh proteins, indicating 
the patient and donor are not truly Rh-matched.  The 
antibodies are often identified as “autoantibodies,” 
but the fact that the Rh proteins differ in amino acid 
sequence from conventional Rh suggests that these 
antibodies are alloimmune in nature and have the 
potential to compromise RBC survival.
The prevalence of RH alleles that encode altered 
D, C, and e antigens in African Black and mixed eth-
nic groups explains why some SCD patients become 
immunized to Rh, despite conventional Rh antigen 
matching.20–23  RH genotyping is very helpful to find 
compatible donors for patients with complex antibod-
ies to high-prevalence Rh antigens.  Current methods 
for RH genotyping are labor intensive because many 
areas of the genes must be sampled, and Rh-cDNA 
analysis is often necessary to detect hybrid RH 
genes.24  High-throughput RH genotyping platforms 
are under development,25 and, when validated, will 
enable SCD patients who are homozygous for altered 
alleles, and consequently at risk for production of 
alloantibodies to high-incidence Rh antigens, to be 
readily identified.  When partnered with RH screen-
ing of donors, RH genetic matching of these patients, 
for which there is no serologic counterpart, could 
potentially eliminate alloimmunization.
Warm Autoantibodies
Patients presenting with warm autoantibodies and 
a positive DAT often have been recently transfused. 
Complex investigations requiring allogeneic adsorp-
tions are often required to determine the presence 
of underlying alloantibodies, and antigen typing is 
complicated by the presence of contaminating do-
nor RBCs and IgG coating the cells.  An extended 
antigen profile is an important tool to determine the 
antigens to which the patient can become sensitized. 
Reticulocyte separations and treatment of the RBCs 
to remove the IgG is laborious and sometimes unsuc-
cessful.  Molecular testing enables the laboratory to 
predict the extended RBC phenotype.  Knowledge of 
the predicted phenotype of the donor units in inven-
tory would allow the laboratory to select donor units 
predicted to be compatible in the major blood group 
systems.  This approach has the potential to limit 
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alloimmunization and to reduce the number or fre-
quency of repeat allogeneic adsorptions for patients 
requiring ongoing transfusion support.
Patients Who Have Made One Alloantibody
Several studies indicate that patients who have 
made one alloantibody are more likely to produce 
additional antibodies.  The production of an alloanti-
body identifies a responder state, as evidenced by as 
much as a 20-fold increased risk for additional anti-
bodies when compared with the risk of alloantibody 
production with the first-time transfusion event.26 
These observations suggest this group should be 
considered for extended-matching when prioritizing 
patients according to alloimmunization risk.
Female Children and Women of 
Childbearing Age
D status
Approximately 2 percent or more of persons with 
D+ RBCs have an altered RHD that encodes amino 
acid changes in the D protein that result in loss of 
epitopes (partial D) or a decrease in antigen expres-
sion (weak D).  These variations in D expression can 
cause typing discrepancies and uncertainty as to the 
D status.  Of clinical relevance, women with partial 
D are at risk for production of anti-D, whereas those 
with weak D phenotypes only rarely become sensi-
tized.  Clarifying the D status of an obstetric patient 
or woman of childbearing potential is important 
to avoid possible fetal and newborn complications 
related to anti-D, or, at the least, having to closely 
monitor the pregnancy and manage the potential 
risk.  Severe and fatal hemolytic disease as a result 
of anti-D has been reported in women with a partial 
DVI phenotype.27  In contrast, a weak D phenotype 
is rarely associated with alloimmunization risk, and 
no high-titer anti-D or serious complications of preg-
nancy have been reported in women with weak D 
phenotypes.  Unfortunately, serologic testing cannot 
distinguish altered, weak, or partial D, especially in 
the age of monoclonal antibody reagents.28  Altered 
RHD can be identified with RHD genotyping and 
would only have to be performed once if made part 
of the permanent medical record.  Although women 
with an uncertain D status could be treated as 
D– for transfusion and given Rh immune globulin, 
clarifying the D status (rather than simply requesting 
D– donor units) results in responsible stewardship of 
the limited D– blood supply and potentially avoids 
unnecessary administration of a human blood prod-
uct, conserving a limited resource.
Anti-K and anti-c
The production of atypical antibodies can result 
in a high-risk pregnancy.  Ten percent of transfusion 
recipients are potentially exposed to K, and approxi-
mately 18 percent to c.  Severe anemia and HDFN 
have been reported as a result of maternal anti-K or 
anti-c stimulated by transfusion.  Anti-K is present 
in approximately 1 per 1000 pregnant women, and 
40 percent of K+ babies of women with anti-K are 
affected with severe anemia.29  Anti-c can also be of 
significance and was associated with 32 deaths from 
HDFN in England and Wales from 1977 to 1990.30  In 
the United States, 8 of 55 pregnancies complicated 
by anti-c required fetal transfusion,31 and pregnancies 
with mildly or unaffected newborns are subject to 
potential invasive and costly monitoring of the preg-
nancy.  In Europe, exposure to c and K is avoided in 
female recipients under the age of 50, but cost con-
straints have been cited as a principal limitation in 
the United States.  It is now possible to avoid alloim-
munization with a cost-effective method to determine 
the extended antigen profile of all units in inventory.
Considerations
Automated DNA-based typing systems do not 
detect all blood group polymorphisms.  It is essential 
to know which are targeted by the manufacturer. 
Some, but not all, rare samples null for a specific 
blood group system can be detected.  For example, 
the current BioArray HEA BeadChip detects U–, Uvar, 
and HY– Jo(a–) samples, but does not target any 
of the Jk(a–b–), i.e., JKnull or Gregory (Gya–) null. 
Many different genetic backgrounds are associated 
with null phenotypes, and the frequency of each 
can differ among population groups.  Even if the 
manufacturer were to add markers for all the nulls 
currently known, new silent alleles are possible in 
any system and would go undetected.  Silenced al-
leles will result in false-positive DNA-typing results, 
although false positives encountered when screening 
donors for antigen-negative status would not com-
promise patient care because the unit would not be 
selected.  In contrast, false-positive antigen typing 
would be of significance for patient care if the results 
were used for ruling out the presence of the corre-
sponding alloantibody in the serum.  For this reason, 
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this author recommends DNA-based antigen typing 
should not be used as the sole criterion for ruling out 
the presence of an alloantibody in the serum.
For patient testing, turnaround time is also a 
consideration.  Current automated systems require 
about 7 to 8 hours from sample DNA extraction to 
readout.  Although this may be substantially reduced 
in the future, patients urgently requiring transfusion 
could not be given extended-matched units, unless 
DNA testing had been performed previously.  Like 
serologic typing for minor antigens, DNA testing for 
minor antigens would only need to be performed 
once and become part of the patient record.
Summary
Agglutination and antibody-based technology will 
remain an important methodology in the blood bank. 
Antibody-based methods are relatively reliable, are a 
direct measure of antigen expression on the RBCs, 
and are familiar to the profession.  DNA methods can-
not replace serum testing for antibody detection or 
identification.  However, the application of molecular 
genotyping to transfusion medicine practice has the 
potential to dramatically change blood bank testing 
by enabling electronic selection of donor units that 
are antigen matched for recipients at multiple blood 
group loci.  Although production of RBC antibodies 
has been considered a manageable risk following 
blood transfusion, prevention may now be feasible 
with molecular genetics.  This approach holds prom-
ise to improve patient care and transfusion outcomes. 
Although providing extended-matched RBC units 
may not be possible for all patients, it is now possible 
for some.  As genotyping advances, blood inventory 
management systems improve, and efforts focus on 
recruitment of minority donors, more patients could 
receive prospectively extended-matched transfusion. 
An initial step will be to provide some degree of 
extended-matched RBC units for patients with SCD, 
and other patients who have made an alloantibody. 
Women of childbearing potential would also be bet-
ter served by receiving K– and c-matched RBC units 
whenever feasible.  
The challenge for the next decade is to integrate 
DNA-based testing into the donor center and blood 
bank environment, standardize methods, obtain 
FDA approval for labeling donor units, and enhance 
information systems to effectively incorporate and 
use this large volume of information.
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